1
|
Gérard T, Colmant L, Malotaux V, Salman Y, Huyghe L, Quenon L, Dricot L, Ivanoiu A, Lhommel R, Hanseeuw B. The spatial extent of tauopathy on [ 18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2024; 51:1662-1674. [PMID: 38228971 PMCID: PMC11043108 DOI: 10.1007/s00259-024-06603-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Accepted: 01/04/2024] [Indexed: 01/18/2024]
Abstract
PURPOSE [18F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer's disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr). METHODS [18F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions (Braak ≤ 2, Braak ≤ 4, and Braak ≤ 6) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values. RESULTS The EOT in the Braak ≤ 2 region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R2 + 0.08-0.09) with the best correlation observed for EOT in the Braak ≤ 4 region (R2 = 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values. CONCLUSIONS Quantifying [18F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD.
Collapse
Affiliation(s)
- Thomas Gérard
- Nuclear Medicine Department, Cliniques Universitaires Saint Luc, Brussels, Belgium.
- Institute of Neurosciences, Université Catholique de Louvain, Brussels, Belgium.
| | - Lise Colmant
- Institute of Neurosciences, Université Catholique de Louvain, Brussels, Belgium
- Neurology Department, Cliniques Universitaires Saint Luc, Brussels, Belgium
| | - Vincent Malotaux
- Institute of Neurosciences, Université Catholique de Louvain, Brussels, Belgium
| | - Yasmine Salman
- Institute of Neurosciences, Université Catholique de Louvain, Brussels, Belgium
| | - Lara Huyghe
- Institute of Neurosciences, Université Catholique de Louvain, Brussels, Belgium
| | - Lisa Quenon
- Institute of Neurosciences, Université Catholique de Louvain, Brussels, Belgium
- Neurology Department, Cliniques Universitaires Saint Luc, Brussels, Belgium
| | - Laurence Dricot
- Institute of Neurosciences, Université Catholique de Louvain, Brussels, Belgium
| | - Adrian Ivanoiu
- Institute of Neurosciences, Université Catholique de Louvain, Brussels, Belgium
- Neurology Department, Cliniques Universitaires Saint Luc, Brussels, Belgium
| | - Renaud Lhommel
- Nuclear Medicine Department, Cliniques Universitaires Saint Luc, Brussels, Belgium
- Institute of Neurosciences, Université Catholique de Louvain, Brussels, Belgium
| | - Bernard Hanseeuw
- Institute of Neurosciences, Université Catholique de Louvain, Brussels, Belgium
- Neurology Department, Cliniques Universitaires Saint Luc, Brussels, Belgium
- WELBIO Department, WEL Research Institute, Avenue Pasteur, 6, 1300, Wavre, Belgium
- Department of Radiology, Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
2
|
Hesse M, Dupont F, Mourad N, Babczenko P, Beaurin G, Xhema D, Bonaccorsi-Riani E, Jamar F, Lhommel R. Kidney dynamic SPECT acquisition on a CZT swiveling-detector ring camera: an in vivo pilot study. BMC Med Imaging 2024; 24:94. [PMID: 38649862 PMCID: PMC11036633 DOI: 10.1186/s12880-024-01271-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2024] [Accepted: 04/08/2024] [Indexed: 04/25/2024] Open
Abstract
BACKGROUND Large field of view CZT SPECT cameras with a ring geometry are available for some years now. Thanks to their good sensitivity and high temporal resolution, general dynamic SPECT imaging may be performed more easily, without resorting to dedicated systems. To evaluate the dynamic SPECT imaging by such cameras, we have performed an in vivo pilot study to analyze the kidney function of a pig and compare the results to standard dynamic planar imaging by a conventional gamma camera. METHODS A 7-week-old (12 kg) female Landrace pig was injected with [99mTc]Tc-MAG3 and a 30 min dynamic SPECT acquisition of the kidneys was performed on a CZT ring camera. A fast SPECT/CT was acquired with the same camera immediately after the dynamic SPECT, without moving the pig, and used for attenuation correction and drawing regions of interest. The next day the same pig underwent a dynamic planar imaging of the kidneys by a conventional 2-head gamma camera. The dynamic SPECT acquisition was reconstructed using a MLEM algorithm with up to 20 iterations, with and without attenuation correction. Time-activity curves of the total counts of each kidney were extracted from 2D and 3D dynamic images. An adapted 2-compartment model was derived to fit the data points and extract physiological parameters. Comparison of these parameters was performed between the different reconstructions and acquisitions. RESULTS Time-activity curves were nicely fitted with the 2-compartment model taking into account the anesthesia and bladder filling. Kidney physiological parameters were found in agreement with literature values. Good agreement of these parameters was obtained for the right kidney between dynamic SPECT and planar imaging. Regional analysis of the kidneys can be performed in the case of the dynamic SPECT imaging and provided good agreement with the whole kidney results. CONCLUSIONS Dynamic SPECT imaging is feasible with CZT swiveling-detector ring cameras and provides results in agreement with dynamic planar imaging by conventional gamma cameras. Regional analysis of organs uptake and clearance becomes possible. Further studies are required regarding the optimization of acquisition and reconstruction parameters to improve image quality and enable absolute quantification.
Collapse
Affiliation(s)
- Michel Hesse
- Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium.
| | - Florian Dupont
- Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium
| | - Nizar Mourad
- Pôle de Chirurgie Expérimentale et Transplantation- CHEX, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Pavel Babczenko
- Pôle de Chirurgie Expérimentale et Transplantation- CHEX, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Gwen Beaurin
- Pôle de Chirurgie Expérimentale et Transplantation- CHEX, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Daela Xhema
- Pôle de Chirurgie Expérimentale et Transplantation- CHEX, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Eliano Bonaccorsi-Riani
- Pôle de Chirurgie Expérimentale et Transplantation- CHEX, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - François Jamar
- Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium
| | - Renaud Lhommel
- Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200, Brussels, Belgium
| |
Collapse
|
3
|
Seront E, Reichel C, Lhommel R, Tombal B. A Case Series Study of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Early Evaluation of the Response to Systemic Therapy in Metastatic Renal Cancer. Eur Urol Oncol 2024:S2588-9311(24)00051-8. [PMID: 38453597 DOI: 10.1016/j.euo.2024.02.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2023] [Revised: 02/01/2024] [Accepted: 02/23/2024] [Indexed: 03/09/2024]
Affiliation(s)
- Emmanuel Seront
- Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Department of Medical Oncology, Centre Universitaire HELORA, Haine Saint Paul, Belgium.
| | - Cédric Reichel
- Department of Nuclear Medicine, Centre Universitaire HELORA, Haine Saint Paul, Belgium
| | - Renaud Lhommel
- Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Bertrand Tombal
- Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| |
Collapse
|
4
|
Colmant L, Boyer E, Gerard T, Sleegers K, Lhommel R, Ivanoiu A, Lefèvre P, Kienlen-Campard P, Hanseeuw B. Definition of a Threshold for the Plasma Aβ42/Aβ40 Ratio Measured by Single-Molecule Array to Predict the Amyloid Status of Individuals without Dementia. Int J Mol Sci 2024; 25:1173. [PMID: 38256246 PMCID: PMC10816992 DOI: 10.3390/ijms25021173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Revised: 01/15/2024] [Accepted: 01/16/2024] [Indexed: 01/24/2024] Open
Abstract
Alzheimer's disease (AD) is characterized by amyloid beta (Aβ) plaques and hyperphosphorylated tau in the brain. Aβ plaques precede cognitive impairments and can be detected through amyloid-positron emission tomography (PET) or in cerebrospinal fluid (CSF). Assessing the plasma Aβ42/Aβ40 ratio seems promising for non-invasive and cost-effective detection of brain Aβ accumulation. This approach involves some challenges, including the accuracy of blood-based biomarker measurements and the establishment of clear, standardized thresholds to categorize the risk of developing brain amyloid pathology. Plasma Aβ42/Aβ40 ratio was measured in 277 volunteers without dementia, 70 AD patients and 18 non-AD patients using single-molecule array. Patients (n = 88) and some volunteers (n = 66) were subject to evaluation of amyloid status by CSF Aβ quantification or PET analysis. Thresholds of plasma Aβ42/Aβ40 ratio were determined based on a Gaussian mixture model, a decision tree, and the Youden's index. The 0.0472 threshold, the one with the highest sensitivity, was retained for general population without dementia screening, and the 0.0450 threshold was retained for research and clinical trials recruitment, aiming to minimize the need for CSF or PET analyses to identify amyloid-positive individuals. These findings offer a promising step towards a cost-effective method for identifying individuals at risk of developing AD.
Collapse
Affiliation(s)
- Lise Colmant
- Institute of Neuroscience, UCLouvain, 1200 Brussels, Belgium; (L.C.); (E.B.); (T.G.); (P.L.); (P.K.-C.)
- Neurology Department, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium;
- Institute of Information and Communication Technologies, Electronics and Applied Mathematics, UCLouvain, 1348 Louvain-la-Neuve, Belgium
| | - Emilien Boyer
- Institute of Neuroscience, UCLouvain, 1200 Brussels, Belgium; (L.C.); (E.B.); (T.G.); (P.L.); (P.K.-C.)
- Neurology Department, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium;
| | - Thomas Gerard
- Institute of Neuroscience, UCLouvain, 1200 Brussels, Belgium; (L.C.); (E.B.); (T.G.); (P.L.); (P.K.-C.)
- Neurology Department, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium;
| | - Kristel Sleegers
- Complex Genetics of Alzheimer’s Disease Group, VIB-UAntwerp Center for Molecular Neurology, University of Antwerp, 2000 Antwerpen, Belgium;
| | - Renaud Lhommel
- Neurology Department, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium;
| | - Adrian Ivanoiu
- Institute of Neuroscience, UCLouvain, 1200 Brussels, Belgium; (L.C.); (E.B.); (T.G.); (P.L.); (P.K.-C.)
- Neurology Department, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium;
| | - Philippe Lefèvre
- Institute of Neuroscience, UCLouvain, 1200 Brussels, Belgium; (L.C.); (E.B.); (T.G.); (P.L.); (P.K.-C.)
- Institute of Information and Communication Technologies, Electronics and Applied Mathematics, UCLouvain, 1348 Louvain-la-Neuve, Belgium
| | - Pascal Kienlen-Campard
- Institute of Neuroscience, UCLouvain, 1200 Brussels, Belgium; (L.C.); (E.B.); (T.G.); (P.L.); (P.K.-C.)
| | - Bernard Hanseeuw
- Institute of Neuroscience, UCLouvain, 1200 Brussels, Belgium; (L.C.); (E.B.); (T.G.); (P.L.); (P.K.-C.)
- Neurology Department, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium;
- WELBIO Department, WEL Research Institute, Avenue Pasteur, 6, 1300 Wavre, Belgium
| |
Collapse
|
5
|
Malotaux V, Colmant L, Quenon L, Huyghe L, Gérard T, Dricot L, Ivanoiu A, Lhommel R, Hanseeuw B. Suspecting Non-Alzheimer's Pathologies and Mixed Pathologies: A Comparative Study Between Brain Metabolism and Tau Images. J Alzheimers Dis 2024; 97:421-433. [PMID: 38108350 PMCID: PMC10789317 DOI: 10.3233/jad-230696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/27/2023] [Indexed: 12/19/2023]
Abstract
BACKGROUND Alzheimer's disease (AD) pathology can be disclosed in vivo using amyloid and tau imaging, unlike non-AD neuropathologies for which no specific markers exist. OBJECTIVE We aimed to compare brain hypometabolism and tauopathy to unveil non-AD pathologies. METHODS Sixty-one patients presenting cognitive complaints (age 48-90), including 32 with positive AD biomarkers (52%), performed [18F]-Fluorodeoxyglucose (FDG)-PET (brain metabolism) and [18F]-MK-6240-PET (tau). We normalized these images using data from clinically normal individuals (n = 30), resulting in comparable FDG and tau z-scores. We computed between-patients correlations to evaluate regional associations. For each patient, a predominant biomarker (i.e., Hypometabolism > Tauopathy or Hypometabolism≤Tauopathy) was determined in the temporal and frontoparietal lobes. We computed within-patient correlations between tau and metabolism and investigated their associations with demographics, cognition, cardiovascular risk factors (CVRF), CSF biomarkers, and white matter hypointensities (WMH). RESULTS We observed negative associations between tau and FDG in 37 of the 68 cortical regions-of-interest (average Pearson's r = -0.25), mainly in the temporal lobe. Thirteen patients (21%) had Hypometabolism > Tauopathy whereas twenty-five patients (41%) had Hypometabolism≤Tauopathy. Tau-predominant patients were more frequently females and had greater amyloid burden. Twenty-three patients (38%) had Hypometabolism≤Tauopathy in the temporal lobe, but Hypometabolism > Tauopathy in the frontoparietal lobe. This group was older and had higher CVRF than Tau-predominant patients. Patients with more negative associations between tau and metabolism were younger, had worse cognition, and greater amyloid and WMH burdens. CONCLUSIONS Tau-FDG comparison can help suspect non-AD pathologies in patients presenting cognitive complaints. Stronger Tau-FDG correlations are associated with younger age, worse cognition, and greater amyloid and WMH burdens.
Collapse
Affiliation(s)
- Vincent Malotaux
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
| | - Lise Colmant
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
- Department of Neurology, Saint-Luc University Hospital, Brussels, Belgium
| | - Lisa Quenon
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
- Department of Neurology, Saint-Luc University Hospital, Brussels, Belgium
| | - Lara Huyghe
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
| | - Thomas Gérard
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
- Department of Nuclear Medicine, Saint-Luc University Hospital, Brussels, Belgium
| | - Laurence Dricot
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
| | - Adrian Ivanoiu
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
- Department of Neurology, Saint-Luc University Hospital, Brussels, Belgium
| | - Renaud Lhommel
- Department of Nuclear Medicine, Saint-Luc University Hospital, Brussels, Belgium
| | - Bernard Hanseeuw
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
- Department of Neurology, Saint-Luc University Hospital, Brussels, Belgium
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- WEL Research Institute, Welbio department, Wavre, Belgium
| |
Collapse
|
6
|
Balligand JL, Brito D, Brosteanu O, Casadei B, Depoix C, Edelmann F, Ferreira V, Filippatos G, Gerber B, Gruson D, Hasenclever D, Hellenkamp K, Ikonomidis I, Krakowiak B, Lhommel R, Mahmod M, Neubauer S, Persu A, Piechnik S, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M, Trochu JN, Van Overstraeten N, Wachter R, Pouleur AC. Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial. JAMA Cardiol 2023; 8:1031-1040. [PMID: 37728907 PMCID: PMC10512168 DOI: 10.1001/jamacardio.2023.3003] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 07/23/2023] [Indexed: 09/22/2023]
Abstract
Importance Left ventricular (LV) hypertrophy contributes to the onset and progression of heart failure (HF), particularly for patients with pre-HF (stage B) for whom no treatment has yet proven effective to prevent transition to overt HF (stage C). The β3-adrenergic receptors (β3ARs) may represent a new target, as their activation attenuates LV remodeling. Objective To determine whether activation of β3ARs by repurposing a β3AR agonist, mirabegron, is safe and effective in preventing progression of LV hypertrophy and diastolic dysfunction among patients with pre- or mild HF. Design, Setting, and Participants The Beta3-LVH prospective, triple-blind, placebo-controlled phase 2b randomized clinical trial enrolled patients between September 12, 2016, and February 26, 2021, with a follow-up of 12 months. The trial was conducted at 10 academic hospitals in 8 countries across Europe (Germany, Poland, France, Belgium, Italy, Portugal, Greece, and the UK). Patients aged 18 years or older with or without HF symptoms (maximum New York Heart Association class II) were screened for the presence of LV hypertrophy (increased LV mass index [LVMI] of ≥95 g/m2 for women or ≥115 g/m2 for men) or maximum wall thickness of 13 mm or greater using echocardiography. Data analysis was performed in August 2022. Intervention Participants were randomly assigned (1:1) to mirabegron (50 mg/d) or placebo, stratified by the presence of atrial fibrillation and/or type 2 diabetes, for 12 months. Main Outcomes and Measures The primary end points were LVMI determined using cardiac magnetic resonance imaging and LV diastolic function (early diastolic tissue Doppler velocity [E/e'] ratio assessed using Doppler echocardiography) at 12 months. Patients with at least 1 valid measurement of either primary end point were included in the primary analysis. Safety was assessed for all patients who received at least 1 dose of study medication. Results Of the 380 patients screened, 296 were enrolled in the trial. There were 147 patients randomized to mirabegron (116 men [79%]; mean [SD] age, 64.0 [10.2] years) and 149 to placebo (112 men [75%]; mean [SD] age, 62.2 [10.9] years). All patients were included in the primary intention-to-treat analysis. At 12 months, the baseline and covariate-adjusted differences between groups included a 1.3-g/m2 increase in LVMI (95% CI, -0.15 to 2.74; P = .08) and a -0.15 decrease in E/e' (95% CI, -0.69 to 0.4; P = .60). A total of 213 adverse events (AEs) occurred in 82 mirabegron-treated patients (including 31 serious AEs in 19 patients) and 215 AEs occurred in 88 placebo-treated patients (including 30 serious AEs in 22 patients). No deaths occurred during the trial. Conclusions In this study, mirabegron therapy had a neutral effect on LV mass or diastolic function over 12 months among patients who had structural heart disease with no or mild HF symptoms. Trial Registration ClinicalTrials.gov Identifier: NCT02599480.
Collapse
Affiliation(s)
- Jean-Luc Balligand
- Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Dulce Brito
- Department of Cardiology, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal
- Centro Académico de Medicina de Lisboa, Universidade de Lisboa, Lisboa, Portugal
- Faculdade de Medicina, Centro Cardiovascular, Universidade de Lisboa, Lisboa, Portugal
| | - Oana Brosteanu
- Clinical Trial Centre Leipzig, Universität Leipzig, Leipzig, Germany
| | - Barbara Casadei
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, Oxford, United Kingdom
- National Institute of Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom
| | - Christophe Depoix
- Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Frank Edelmann
- Department of Cardiology, German Centre for Cardiovascular Research, Charité University Campus Virchow, Berlin, Germany
| | - Vanessa Ferreira
- Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, United Kingdom
| | - Gerasimos Filippatos
- Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece
| | - Bernhard Gerber
- Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Damien Gruson
- Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Dirk Hasenclever
- Institute for Medical Informatics, Statistics, and Epidemiology, Universität Leipzig, Leipzig, Germany
| | - Kristian Hellenkamp
- Department of Cardiology and Pneumology, German Centre for Cardiovascular Research, Universitätsmedizin Göttingen, Göttingen, Germany
| | - Ignatios Ikonomidis
- Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece
| | - Bartosz Krakowiak
- Department of Cardiology, Centre for Heart Diseases, Clinical Military Hospital, Wrocław Medical University, Wrocław, Poland
| | - Renaud Lhommel
- Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Masliza Mahmod
- Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, United Kingdom
| | - Stefan Neubauer
- Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, United Kingdom
| | - Alexandre Persu
- Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Stefan Piechnik
- Radcliffe Department of Medicine, Oxford Centre for Clinical Magnetic Resonance Research, University of Oxford, Oxford, United Kingdom
| | - Burkert Pieske
- Department of Cardiology, German Centre for Cardiovascular Research, Charité University Campus Virchow, Berlin, Germany
| | - Elisabeth Pieske-Kraigher
- Department of Cardiology, German Centre for Cardiovascular Research, Charité University Campus Virchow, Berlin, Germany
| | - Fausto Pinto
- Department of Cardiology, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal
- Centro Académico de Medicina de Lisboa, Universidade de Lisboa, Lisboa, Portugal
- Faculdade de Medicina, Centro Cardiovascular, Universidade de Lisboa, Lisboa, Portugal
| | - Piotr Ponikowski
- Department of Cardiology, Centre for Heart Diseases, Clinical Military Hospital, Wrocław Medical University, Wrocław, Poland
| | - Michele Senni
- Department of Cardiology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, University of Milano-Bicocca, Bergamo, Italy
| | - Jean-Noël Trochu
- Institut du Thorax, Centre National de la Recherche Scientifique, Nantes Université, Nantes, France
- L’Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France
| | - Nancy Van Overstraeten
- Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Rolf Wachter
- Department of Cardiology and Pneumology, German Centre for Cardiovascular Research, Universitätsmedizin Göttingen, Göttingen, Germany
- Department of Cardiology, University Hospital Leipzig, Leipzig, Germany
| | - Anne-Catherine Pouleur
- Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| |
Collapse
|
7
|
d’Abadie P, Gheysens O, Lhommel R, Jamar F, Kirchgesner T, Mazzeo F, Coubeau L, Yildiz H, De Roo AK, Schubert T. Diagnostic Superiority of Dual-Time Point [ 18F]FDG PET/CT to Differentiate Malignant from Benign Soft Tissue Tumors. Diagnostics (Basel) 2023; 13:3202. [PMID: 37892023 PMCID: PMC10606132 DOI: 10.3390/diagnostics13203202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 10/09/2023] [Accepted: 10/10/2023] [Indexed: 10/29/2023] Open
Abstract
[18F]FDG PET/CT is used in the workup of indeterminate soft tissue tumors (STTs) but lacks accuracy in the detection of malignant STTs. The aim of this study is to evaluate whether dual-time point [18F]FDG PET/CT imaging (DTPI) can be useful in this indication. In this prospective study, [18F]FDG PET/CT imaging was performed 1 h (t1) and 3 h (t2) after injection. Tumor uptake (SUVmax) was calculated at each time point to define a retention index (RI) corresponding to the variation between t1 and t2 (%). Sixty-eight patients were included, representing 20 benign and 48 malignant tumors (including 40 sarcomas). The RI was significantly higher in malignant STTs than in benign STTs (median: +21.8% vs. -2%, p < 0.001). An RI of >14.3% predicted STT malignancy with a specificity (Sp) of 90% and a sensitivity (Se) of 69%. An SUVmaxt1 of >4.5 was less accurate with an Sp of 80% and an Se of 60%. In a subgroup of tumors with at least mild [18F]FDG uptake (SUVmax ≥ 3; n = 46), the RI significantly outperformed the diagnostic accuracy of SUVmax (AUC: 0.88 vs. 0.68, p = 0.01). DTPI identifies malignant STT tumors with high specificity and outperforms the diagnostic accuracy of standard PET/CT.
Collapse
Affiliation(s)
- Philippe d’Abadie
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc-Institut Roi Albert II, Université Catholique de Louvain, 1200 Brussels, Belgium; (O.G.); (R.L.); (F.J.)
| | - Olivier Gheysens
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc-Institut Roi Albert II, Université Catholique de Louvain, 1200 Brussels, Belgium; (O.G.); (R.L.); (F.J.)
| | - Renaud Lhommel
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc-Institut Roi Albert II, Université Catholique de Louvain, 1200 Brussels, Belgium; (O.G.); (R.L.); (F.J.)
| | - François Jamar
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc-Institut Roi Albert II, Université Catholique de Louvain, 1200 Brussels, Belgium; (O.G.); (R.L.); (F.J.)
| | - Thomas Kirchgesner
- Department of Radiology, Cliniques Universitaires Saint Luc-Institut Roi Albert II, Université Catholique de Louvain, 1200 Brussels, Belgium;
| | - Filomena Mazzeo
- Department of Clinical Oncology, Cliniques Universitaires Saint Luc-Institut Roi Albert II, Université Catholique de Louvain, 1200 Brussels, Belgium;
| | - Laurent Coubeau
- Department of Abdominal Surgery, Cliniques Universitaires Saint Luc-Institut Roi Albert II, Université Catholique de Louvain, 1200 Brussels, Belgium;
| | - Halil Yildiz
- Department of Internal Medicine, Cliniques Universitaires Saint Luc-Institut Roi Albert II, Université Catholique de Louvain, 1200 Brussels, Belgium;
| | - An-Katrien De Roo
- Department of Pathology, Cliniques Universitaires Saint Luc-Institut Roi Albert II, Université Catholique de Louvain, 1200 Brussels, Belgium;
| | - Thomas Schubert
- Department of Orthopedic Surgery, Cliniques Universitaires Saint Luc-Institut Roi Albert II, Université Catholique de Louvain, 1200 Brussels, Belgium;
| |
Collapse
|
8
|
Noortman WA, Aide N, Vriens D, Arkes LS, Slump CH, Boellaard R, Goeman JJ, Deroose CM, Machiels JP, Licitra LF, Lhommel R, Alessi A, Woff E, Goffin K, Le Tourneau C, Gal J, Temam S, Delord JP, van Velden FHP, de Geus-Oei LF. Development and External Validation of a PET Radiomic Model for Prognostication of Head and Neck Cancer. Cancers (Basel) 2023; 15:2681. [PMID: 37345017 DOI: 10.3390/cancers15102681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 04/30/2023] [Accepted: 05/03/2023] [Indexed: 06/23/2023] Open
Abstract
AIM To build and externally validate an [18F]FDG PET radiomic model to predict overall survival in patients with head and neck squamous cell carcinoma (HNSCC). METHODS Two multicentre datasets of patients with operable HNSCC treated with preoperative afatinib who underwent a baseline and evaluation [18F]FDG PET/CT scan were included (EORTC: n = 20, Unicancer: n = 34). Tumours were delineated, and radiomic features were extracted. Each cohort served once as a training and once as an external validation set for the prediction of overall survival. Supervised feature selection was performed using variable hunting with variable importance, selecting the top two features. A Cox proportional hazards regression model using selected radiomic features and clinical characteristics was fitted on the training dataset and validated in the external validation set. Model performances are expressed by the concordance index (C-index). RESULTS In both models, the radiomic model surpassed the clinical model with validation C-indices of 0.69 and 0.79 vs. 0.60 and 0.67, respectively. The model that combined the radiomic features and clinical variables performed best, with validation C-indices of 0.71 and 0.82. CONCLUSION Although assessed in two small but independent cohorts, an [18F]FDG-PET radiomic signature based on the evaluation scan seems promising for the prediction of overall survival for HNSSC treated with preoperative afatinib. The robustness and clinical applicability of this radiomic signature should be assessed in a larger cohort.
Collapse
Affiliation(s)
- Wyanne A Noortman
- Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
- TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands
| | - Nicolas Aide
- Nuclear Medicine Department, Centre Hospitalier Universitaire de Caen, 14000 Caen, France
| | - Dennis Vriens
- Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
| | - Lisa S Arkes
- Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
- Technical Medicine, Delft University of Technology, 2628 CD Delft, The Netherlands
| | - Cornelis H Slump
- TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands
| | - Ronald Boellaard
- Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands
| | - Jelle J Goeman
- Department of Biomedical Data Sciences, Leiden University Medical Center, 2300 RC Leiden, The Netherlands
| | - Christophe M Deroose
- Nuclear Medicine and Molecular Imaging, Department of Imaging & Pathology, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium
| | - Jean-Pascal Machiels
- Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium
- Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium
| | - Lisa F Licitra
- Department of Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, 20133 Milan, Italy
| | - Renaud Lhommel
- Division of Nuclear Medicine, Institut de Recherche Clinique, Cliniques Universitaires Saint Luc, 1200 Brussels, Belgium
| | - Alessandra Alessi
- Department of Nuclear Medicine-PET Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
| | - Erwin Woff
- Nuclear Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), 1070 Bruxelles, Belgium
| | - Karolien Goffin
- Nuclear Medicine and Molecular Imaging, Department of Imaging & Pathology, University Hospitals Leuven, KU Leuven, 3000 Leuven, Belgium
| | - Christophe Le Tourneau
- Department of Drug Development and Innovation, Institut Curie, Paris-Saclay University, 75005 Paris, France
| | - Jocelyn Gal
- Epidemiology and Biostatistics Department, Centre Antoine Lacassagne, University Côte d'Azur, 06100 Nice, France
| | - Stéphane Temam
- Department of Head and Neck Surgery Gustave Roussy, 94805 Villejuif, France
| | | | - Floris H P van Velden
- Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
| | - Lioe-Fee de Geus-Oei
- Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
- TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands
- Department of Radiation Science & Technology, Delft University of Technology, 2628 CD Delft, The Netherlands
| |
Collapse
|
9
|
Malotaux V, Dricot L, Quenon L, Gérard T, Ivanoiu A, Lhommel R, Hanseeuw BJ. Associations between FDG metabolism and fMRI connectivity in the default mode network depend on Aβ status in MCI patients. Alzheimers Dement 2022. [DOI: 10.1002/alz.069059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | - Lisa Quenon
- Institute of Neuroscience, UCLouvain Brussels Belgium
- Saint‐Luc University Hospital Brussels Belgium
| | - Thomas Gérard
- Institute of Neuroscience, UCLouvain Brussels Belgium
| | - Adrian Ivanoiu
- Institute of Neuroscience, UCLouvain Brussels Belgium
- Saint‐Luc University Hospital Brussels Belgium
| | - Renaud Lhommel
- Institute of Neuroscience, UCLouvain Brussels Belgium
- Saint‐Luc University Hospital Brussels Belgium
| | - Bernard J Hanseeuw
- Institute of Neuroscience, UCLouvain Brussels Belgium
- Saint‐Luc University Hospital Brussels Belgium
- Massachussets General Hospital, Harvard Medical School Boston USA
| |
Collapse
|
10
|
Malotaux V, Dricot L, Quenon L, Lhommel R, Ivanoiu A, Hanseeuw B. Default-mode network connectivity changes during the progression towards Alzheimer’s dementia: A longitudinal functional MRI study. Brain Connect 2022. [DOI: 10.1089/brain.2022.0008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Vincent Malotaux
- Université catholique de Louvain, Institute of Neuroscience, Avenue Emmanuel Mounier, 54, Brussels, Belgium, 1200
| | - Laurence Dricot
- Université catholique de Louvain, Institute of Neuroscience, Brussels, Belgium
| | - Lisa Quenon
- Université catholique de Louvain, Institute of Neuroscience, Brussels, Belgium
- University Hospital Saint-Luc, Neurology Department, Brussels, Belgium
| | - Renaud Lhommel
- University Hospital Saint-Luc, Nuclear Medicine Department, Brussels, Belgium
- Université catholique de Louvain, Institute of Neuroscience, Brussels, Belgium
| | - Adrian Ivanoiu
- Université catholique de Louvain, Institute of Neuroscience, Brussels, Belgium
- University Hospital Saint-Luc, Neurology Department, Brussels, Belgium
| | - Bernard Hanseeuw
- Université catholique de Louvain, Institute of Neuroscience, Brussels, Belgium
- University Hospital Saint-Luc, Neurology Department, Brussels, Belgium
- Harvard Medical School, Massachusetts General Hospital, Radiology Department, Boston, Massachusetts, United States
- Walloon Excellence in Lifesciences and Biotechnology, Wavre, Belgium
| |
Collapse
|
11
|
d'Abadie P, Walrand S, Hesse M, Borbath I, Lhommel R, Jamar F. TCP post-radioembolization and TCP post-EBRT in HCC are similar and can be predicted using the in vitro radiosensitivity. EJNMMI Res 2022; 12:40. [PMID: 35802307 PMCID: PMC9270555 DOI: 10.1186/s13550-022-00911-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Accepted: 06/26/2022] [Indexed: 11/13/2022] Open
Abstract
Background Tumor equivalent uniform dose (EUD) is proposed as a predictor of patient outcome after liver radioembolization (RE) of hepatocellular carcinoma (HCC) and can be evaluated with 90Y-TOF-PET. The aim is to evaluate the correlation between PET-based tumors EUD and the clinical response evaluated with dual molecular tracer (11C-acetate and 18F-FDG) PET/CT post-RE. Methods 34 HCC tumors in 22 patients were prospectively evaluated. The metabolic response was characterized by the total lesion metabolism variation (ΔTLM) between baseline and follow-up. This response allowed to compute a tumor control probability (TCP) as a function of the tumor EUD. Results The absorbed dose response correlation was highly significant (R = 0.72, P < 0.001). With an absorbed dose threshold of 40 Gy, the metabolic response was strongly different in both groups (median response 35% versus 100%, P < 0.001). Post-RE TCP as a function of the EUD was very similar to that observed in external beam radiation therapy (EBRT), with TCP values equal to 0.5 and 0.95 for a EUD of 51 Gy and 100 Gy, respectively. The TCP was perfectly predicted by the Poisson model assuming an inter tumor radiosensitivity variation of 30% around the HCC cell in vitro value. Conclusions EUD-based 90Y TOF-PET/CT predicts the metabolic response post-RE in HCC assessed using dual molecular PET tracers and provides a similar TCP curve to that observed in EBRT. In vivo and in vitro HCC radiosensitivities are similar. Both TCPs show that a EUD of 100 Gy is needed to control HCC for the three devices (resin spheres, glass spheres, EBRT). Observed absorbed doses achieving this 100 Gy-EUD ranged from 190 to 1800 Gy! Supplementary Information The online version contains supplementary material available at 10.1186/s13550-022-00911-0.
Collapse
Affiliation(s)
- Philippe d'Abadie
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Institut Roi Albert II, 10, avenue Hippocrate, 1200, Brussels, Belgium.
| | - Stephan Walrand
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Institut Roi Albert II, 10, avenue Hippocrate, 1200, Brussels, Belgium
| | - Michel Hesse
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Institut Roi Albert II, 10, avenue Hippocrate, 1200, Brussels, Belgium
| | - Ivan Borbath
- Department of Medical Oncology, CIiniques Universitaires Saint Luc, Institut Roi Albert II, Brussels, Belgium
| | - Renaud Lhommel
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Institut Roi Albert II, 10, avenue Hippocrate, 1200, Brussels, Belgium
| | - François Jamar
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Institut Roi Albert II, 10, avenue Hippocrate, 1200, Brussels, Belgium
| |
Collapse
|
12
|
d’Abadie P, Walrand S, Lhommel R, Hesse M, Borbath I, Jamar F. Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Curr Oncol 2022; 29:2422-2434. [PMID: 35448170 PMCID: PMC9024927 DOI: 10.3390/curroncol29040196] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Revised: 03/26/2022] [Accepted: 03/28/2022] [Indexed: 02/05/2023] Open
Abstract
Selective internal radiation therapy (SIRT) is part of the treatment strategy for hepatocellular carcinoma (HCC). Strong clinical data demonstrated the effectiveness of this therapy in HCC with a significant improvement in patient outcomes. Recent studies demonstrated a strong correlation between the tumor response and the patient outcome when the tumor-absorbed dose was assessed by nuclear medicine imaging. Dosimetry plays a key role in predicting the clinical response and can be optimized using a personalized method of activity planning (multi-compartmental dosimetry). This paper reviews the main clinical results of SIRT in HCC and emphasizes the central role of dosimetry for improving it effectiveness. Moreover, some patient and tumor characteristics predict a worse outcome, and toxicity related to SIRT treatment of advanced HCC patient selection based on the performance status, liver function, tumor characteristics, and tumor targeting using technetium-99m macro-aggregated albumin scintigraphy can significantly improve the clinical performance of SIRT.
Collapse
Affiliation(s)
- Philippe d’Abadie
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Brussels, Belgium; (S.W.); (R.L.); (M.H.); (F.J.)
- Correspondence: ; Tel.: +32-2764-7944
| | - Stephan Walrand
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Brussels, Belgium; (S.W.); (R.L.); (M.H.); (F.J.)
| | - Renaud Lhommel
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Brussels, Belgium; (S.W.); (R.L.); (M.H.); (F.J.)
| | - Michel Hesse
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Brussels, Belgium; (S.W.); (R.L.); (M.H.); (F.J.)
| | - Ivan Borbath
- Department of Gastroenterology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Brussels, Belgium;
| | - François Jamar
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Brussels, Belgium; (S.W.); (R.L.); (M.H.); (F.J.)
| |
Collapse
|
13
|
Devresse A, Lhommel R, Godefroid N, Goffin E, Kanaan N. 18-Fluorodeoxyglucose positron emission computed tomography for systemic oxalosis in primary hyperoxaluria type 1. Am J Transplant 2022; 22:1001-1002. [PMID: 34741787 DOI: 10.1111/ajt.16887] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 10/19/2021] [Accepted: 10/27/2021] [Indexed: 01/25/2023]
Affiliation(s)
- Arnaud Devresse
- Department of Nephrology, Cliniques universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Renaud Lhommel
- Nuclear Medicine, Cliniques universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Nathalie Godefroid
- Pediatric Nephrology, Cliniques universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Eric Goffin
- Department of Nephrology, Cliniques universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Nada Kanaan
- Department of Nephrology, Cliniques universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium
| |
Collapse
|
14
|
Seront E, Lhommel R, Tombal B. Case Report: Early 68Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases. Front Oncol 2021; 11:782166. [PMID: 34950588 PMCID: PMC8689125 DOI: 10.3389/fonc.2021.782166] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Accepted: 11/16/2021] [Indexed: 01/03/2023] Open
Abstract
Early evaluation of response to anticancer treatment in metastatic renal cell carcinoma (RCC) is challenging as responses are sometimes delayed, as mixed responses can occur, and as conventional imaging have some limitations. As PSMA has been previously identified in neovasculature of clear cell RCC (ccRCC), 68Ga-PSMA-Positron Emitted Tomography (PET) could appear as an interesting tool to evaluate therapeutic response. We describe the association of an early decrease in 68Ga metabolism (at 8 weeks after treatment onset) and further radiological response (at 12 weeks after treatment onset) to treatment in two patients with different sensitivity to axitinib–pembrolizumab combination. Interestingly, one of these patients presented an initial progressive disease on pembrolizumab alone and a subsequent response to axitinib alone in the disease course; these response profiles were associated with absence of decrease and subsequent decrease in the 68Ga metabolism, respectively. Even if further prospective trials are needed, 68Ga-PSMA-PET may appear as a promising way for early prediction of response to ccRCC systemic treatment.
Collapse
Affiliation(s)
- Emmanuel Seront
- Division of Medical Oncology, Institut de Recherche Clinique (IREC), Cliniques Universitaires Saint Luc, Brussels, Belgium
| | - Renaud Lhommel
- Division of Nuclear Medicine, Institut de Recherche Clinique (IREC), Cliniques Universitaires Saint Luc, Brussels, Belgium
| | - Bertrand Tombal
- Division of Urology, Institut de Recherche Clinique (IREC), Cliniques Universitaires Saint Luc, Brussels, Belgium
| |
Collapse
|
15
|
Gérard T, Malotaux V, Ivanoiu A, Lhommel R, Hanseeuw BJ. Correlation between MK‐6240 tau‐PET and CSF tau, P‐tau and amyloid proteins. Alzheimers Dement 2021. [DOI: 10.1002/alz.052062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Thomas Gérard
- Université Catholique de Louvain Brussels Belgium
- Institute of NeuroScience Brussels Belgium
| | - Vincent Malotaux
- Université Catholique de Louvain Brussels Belgium
- Institute of NeuroScience Brussels Belgium
| | - Adrian Ivanoiu
- Université Catholique de Louvain Brussels Belgium
- Institute of Neuroscience UCLouvain Brussels Belgium
| | | | - Bernard J. Hanseeuw
- Université Catholique de Louvain Brussels Belgium
- Institute of Neuroscience UCLouvain Brussels Belgium
| |
Collapse
|
16
|
Malotaux V, Dricot L, Quenon L, Ivanoiu A, Lhommel R, Hanseeuw BJ. Increased intra‐network functional connectivity in MCI patients progressing towards dementia compared to stable MCI. Alzheimers Dement 2021. [DOI: 10.1002/alz.057742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | | | - Lisa Quenon
- Institute of Neuroscience UCLouvain Brussels Belgium
| | - Adrian Ivanoiu
- Institute of Neuroscience UCLouvain Brussels Belgium
- Saint‐Luc University Hospital Brussels Belgium
| | - Renaud Lhommel
- Institute of Neuroscience UCLouvain Brussels Belgium
- Saint‐Luc University Hospital Brussels Belgium
| | - Bernard J. Hanseeuw
- Institute of Neuroscience UCLouvain Brussels Belgium
- Saint‐Luc University Hospital Brussels Belgium
- Massachussets General Hospital Harvard Medical School Boston USA
| |
Collapse
|
17
|
d'Abadie P, Walrand S, Goffette P, Amini N, Maanen AV, Lhommel R, Jamar F. Antireflux catheter improves tumor targeting in liver radioembolization with resin microspheres. Diagn Interv Radiol 2021; 27:768-773. [PMID: 34792032 DOI: 10.5152/dir.2021.20785] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
PURPOSE We aimed to determine whether antireflux (ARC) catheter may result in better tumor targeting in liver radioembolization using 90Y-resin microspheres. METHODS Patients treated with resin microspheres for hepatocellular carcinoma (HCC) and secondary liver malignancies were retrospectively analyzed. All patients underwent a 99mTc-macroaggregated albumin (99mTc-MAA) single photon emission computed tomography (SPECT) following the planning arteriography with a conventional end-hole catheter. For 90Y-microspheres injection, two groups were defined depending on the type of catheter used: an ARC group (n=38) and a control group treated with a conventional end-hole catheter (n=23). 90Y positron emission tomography computed tomography (PET/CT) was performed after the therapeutic arteriography. The choice of the catheter was not randomized, but left to the choice of the interventional radiologist. 99mTc-MAA SPECT and 90Y PET/CT were co-registered with the baseline imaging to determine a tumor to normal liver ratio (T/NL[MAA or 90Y]) and tumor dose (TD[MAA or 90Y]) for the planning and therapy. RESULTS Overall, 38 patients (115 lesions) and 23 patients (75 lesions) were analyzed in the ARC and control groups, respectively. In the ARC group, T/NL90Y and TD90Y were significantly higher than T/NLMAA and TDMAA. Median (IQR) T/NL90Y was 2.16 (2.15) versus 1.74 (1.43) for T/NLMAA (p < 0.001). Median (IQR) TD90Y was 90.96 Gy (98.31 Gy) versus 73.72 Gy (63.82 Gy) for TDMAA (p < 0.001). In this group, the differences were highly significant for neuroendocrine metastases (NEM) and HCC and less significant for colorectal metastases (CRM). In the control group, no significant differences were demonstrated. CONCLUSION The use of an ARC significantly improves tumor deposition in liver radioembolization with resin microspheres.
Collapse
Affiliation(s)
- Philippe d'Abadie
- Department of Nuclear Medicine, Saint Luc University Hospital and King Albert II Cancer Institute, Brussels, Belgium
| | - Stephan Walrand
- Department of Nuclear Medicine, Saint Luc University Hospital and King Albert II Cancer Institute, Brussels, Belgium
| | - Pierre Goffette
- Department of Interventional Radiology, Saint Luc University Hospital and King Albert II cancer Institute, Brussels, Belgium
| | - Nadia Amini
- Department of Interventional Radiology, Saint Luc University Hospital and King Albert II cancer Institute, Brussels, Belgium
| | - Aline van Maanen
- From the Department of Nuclear Medicine Saint Luc University Hospital and King Albert II Cancer Institute, Brussels, Belgium
| | - Renaud Lhommel
- Department of Nuclear Medicine, Saint Luc University Hospital and King Albert II Cancer Institute, Brussels, Belgium
| | - François Jamar
- Department of Nuclear Medicine, Saint Luc University Hospital and King Albert II Cancer Institute, Brussels, Belgium
| |
Collapse
|
18
|
Hesse M, d'Abadie P, Lhommel R, Jamar F, Walrand S. Yttrium-90 TOF-PET-Based EUD Predicts Response Post Liver Radioembolizations Using Recommended Manufacturer FDG Reconstruction Parameters. Front Oncol 2021; 11:592529. [PMID: 34676157 PMCID: PMC8523947 DOI: 10.3389/fonc.2021.592529] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Accepted: 09/07/2021] [Indexed: 11/13/2022] Open
Abstract
Purpose Explaining why 90Y TOF-PET based equivalent uniform dose (EUD) using recommended manufacturer FDG reconstruction parameters has been shown to predict response. Methods The hot rods insert of a Jaszczak deluxe phantom was partially filled with a 2.65 GBq 90Y - 300ml DTPA water solution resulting in a 100 Gy mean absorbed dose in the 6 sectors. A two bed 20min/position acquisition was performed on a 550ps- and on a 320ps- TOF-PET/CT and reconstructed with recommended manufacturer FDG reconstruction parameters, without and with additional filtering. The whole procedure was repeated on both PET after adding 300ml of water (50Gy setup). The phantom was acquired again after decay by a factor of 10 (5Gy setup), but with 200min per bed position. For comparison, the phantom was also acquired with 18F activity corresponding to a clinical FDG whole body acquisition. Results The 100Gy-setup provided a hot rod sectors image almost as good as the 18F phantom. However, despite acquisition time compensation, the 5Gy-setup provides much lower quality imaging. TOF-PET based sectors EUDs for the three large rod sectors agreed with the actual EUDs computed with a radiosensitivity of 0.021Gy-1 well in the range observed in external beam radiotherapy (EBRT), i.e. 0.01-0.04Gy-1. This agreement explains the reunification of the dose-response relationships of the glass and resin spheres in HCC using the TOF-PET based EUD. Additional filtering reduced the EUDs agreement quality. Conclusions Recommended manufacturer FDG reconstruction parameters are suitable in TOF-PET post 90Y liver radioembolization for accurate tumour EUD computation. The present results rule out the use of low specific activity phantom studies to optimize reconstruction parameters.
Collapse
Affiliation(s)
- Michel Hesse
- Nuclear Medicine, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - Philipe d'Abadie
- Nuclear Medicine, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - Renaud Lhommel
- Nuclear Medicine, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - Francois Jamar
- Nuclear Medicine, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - Stephan Walrand
- Nuclear Medicine, Cliniques universitaires Saint-Luc, Brussels, Belgium
| |
Collapse
|
19
|
Van Damme J, Tombal B, Collette L, Van Nieuwenhove S, Pasoglou V, Gérard T, Jamar F, Lhommel R, Lecouvet FE. Comparison of 68Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer. Cancers (Basel) 2021; 13:cancers13215286. [PMID: 34771449 PMCID: PMC8582508 DOI: 10.3390/cancers13215286] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Revised: 10/04/2021] [Accepted: 10/14/2021] [Indexed: 12/12/2022] Open
Abstract
Simple Summary Precise staging is key for the optimal management of advanced prostate cancer. PSMA PET-CT and WB-MRI outperform standard imaging technology for staging high-risk prostate cancer, but direct comparison between both modalities is lacking. The primary endpoint of our study was to compare the diagnostic accuracy of both techniques in the detection of lymph node, bone and visceral metastases against a best valuable comparator (BVC), defined as a consensus adjudication of all lesions on the basis of baseline and follow-up imaging, biological and clinical data and histopathologic confirmation when available. Knowing the diagnostic accuracy of both next generation imaging modalities might influence the diagnostic and therapeutic strategy in prostate cancer by tailoring therapy. However, the impact on treatment and patient outcome of an improved detection of metastases has not been determined yet. Abstract Background: Prostate specific membrane antigen (PSMA) positron emission tomography computed tomography (PET-CT) and whole-body magnetic resonance imaging (WB-MRI) outperform standard imaging technology for the detection of metastasis in prostate cancer (PCa). There are few direct comparisons between both modalities. This paper compares the diagnostic accuracy of PSMA PET-CT and WB-MRI for the detection of metastasis in PCa. One hundred thirty-four patients with newly diagnosed PCa (n = 81) or biochemical recurrence after curative treatment (n = 53) with high-risk features prospectively underwent PSMA PET-CT and WB-MRI. The diagnostic accuracy of both techniques for lymph node, skeletal and visceral metastases was compared against a best valuable comparator (BVC). Overall, no significant difference was detected between PSMA PET-CT and WB-MRI to identify metastatic patients when considering lymph nodes, skeletal and visceral metastases together (AUC = 0.96 (0.92–0.99) vs. 0.90 (0.85–0.95); p = 0.09). PSMA PET-CT, however, outperformed WB-MRI in the subgroup of patients with newly diagnosed PCa for the detection of lymph node metastases (AUC = 0.96 (0.92–0.99) vs. 0.86 (0.79–0.92); p = 0.0096). In conclusion, PSMA PET-CT outperforms WB-MRI for the detection of nodal metastases in primary staging of PCa.
Collapse
Affiliation(s)
- Julien Van Damme
- Department of Urology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium; (J.V.D.); (B.T.)
| | - Bertrand Tombal
- Department of Urology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium; (J.V.D.); (B.T.)
| | - Laurence Collette
- International Drug Development Institute (IDDI), B-1341 Louvain-la-Neuve, Belgium;
| | - Sandy Van Nieuwenhove
- Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC-IMAG), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium; (S.V.N.); (V.P.)
| | - Vassiliki Pasoglou
- Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC-IMAG), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium; (S.V.N.); (V.P.)
| | - Thomas Gérard
- Department of Nuclear Medicine, Institut de Recherche Expérimentale et Clinique (IREC-MIRO), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium; (T.G.); (F.J.); (R.L.)
| | - François Jamar
- Department of Nuclear Medicine, Institut de Recherche Expérimentale et Clinique (IREC-MIRO), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium; (T.G.); (F.J.); (R.L.)
| | - Renaud Lhommel
- Department of Nuclear Medicine, Institut de Recherche Expérimentale et Clinique (IREC-MIRO), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium; (T.G.); (F.J.); (R.L.)
| | - Frédéric E. Lecouvet
- Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC-IMAG), Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, B-1200 Brussels, Belgium; (S.V.N.); (V.P.)
- Correspondence:
| |
Collapse
|
20
|
d’Abadie P, Hesse M, Louppe A, Lhommel R, Walrand S, Jamar F. Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects. Molecules 2021; 26:3966. [PMID: 34209590 PMCID: PMC8271370 DOI: 10.3390/molecules26133966] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 06/22/2021] [Accepted: 06/23/2021] [Indexed: 01/31/2023] Open
Abstract
Inert microspheres, labeled with several radionuclides, have been developed during the last two decades for the intra-arterial treatment of liver tumors, generally called Selective Intrahepatic radiotherapy (SIRT). The aim is to embolize microspheres into the hepatic capillaries, accessible through the hepatic artery, to deliver high levels of local radiation to primary (such as hepatocarcinoma, HCC) or secondary (metastases from several primary cancers, e.g., colorectal, melanoma, neuro-endocrine tumors) liver tumors. Several types of microspheres were designed as medical devices, using different vehicles (glass, resin, poly-lactic acid) and labeled with different radionuclides, 90Y and 166Ho. The relationship between the microspheres' properties and the internal dosimetry parameters have been well studied over the last decade. This includes data derived from the clinics, but also computational data with various millimetric dosimetry and radiobiology models. The main purpose of this paper is to define the characteristics of these radiolabeled microspheres and explain their association with the microsphere distribution in the tissues and with the clinical efficacy and toxicity. This review focuses on avenues to follow in the future to optimize such particle therapy and benefit to patients.
Collapse
Affiliation(s)
- Philippe d’Abadie
- Department of Nuclear Medicine, Cliniques Universitaires Saint Luc, Université Catholique de Louvain, 1200 Brussels, Belgium; (M.H.); (A.L.); (R.L.); (S.W.); (F.J.)
| | | | | | | | | | | |
Collapse
|
21
|
Bucci M, Savitcheva I, Farrar G, Salvadó G, Collij L, Doré V, Gispert JD, Gunn R, Hanseeuw B, Hansson O, Shekari M, Lhommel R, Molinuevo JL, Rowe C, Sur C, Whittington A, Buckley C, Nordberg A. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [ 18F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging 2021; 48:2183-2199. [PMID: 33844055 PMCID: PMC8175298 DOI: 10.1007/s00259-021-05311-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 03/09/2021] [Indexed: 12/18/2022]
Abstract
BACKGROUND [18F]flutemetamol PET scanning provides information on brain amyloid load and has been approved for routine clinical use based upon visual interpretation as either negative (equating to none or sparse amyloid plaques) or amyloid positive (equating to moderate or frequent plaques). Quantitation is however fundamental to the practice of nuclear medicine and hence can be used to supplement amyloid reading methodology especially in unclear cases. METHODS A total of 2770 [18F]flutemetamol images were collected from 3 clinical studies and 6 research cohorts with available visual reading of [18F]flutemetamol and quantitative analysis of images. These were assessed further to examine both the discordance and concordance between visual and quantitative imaging primarily using thresholds robustly established using pathology as the standard of truth. Scans covered a wide range of cases (i.e. from cognitively unimpaired subjects to patients attending the memory clinics). Methods of quantifying amyloid ranged from using CE/510K cleared marked software (e.g. CortexID, Brass), to other research-based methods (e.g. PMOD, CapAIBL). Additionally, the clinical follow-up of two types of discordance between visual and quantitation (V+Q- and V-Q+) was examined with competing risk regression analysis to assess possible differences in prediction for progression to Alzheimer's disease (AD) and other diagnoses (OD). RESULTS Weighted mean concordance between visual and quantitation using the autopsy-derived threshold was 94% using pons as the reference region. Concordance from a sensitivity analysis which assessed the maximum agreement for each cohort using a range of cut-off values was also estimated at approximately 96% (weighted mean). Agreement was generally higher in clinical cases compared to research cases. V-Q+ discordant cases were 11% more likely to progress to AD than V+Q- for the SUVr with pons as reference region. CONCLUSIONS Quantitation of amyloid PET shows a high agreement vs binary visual reading and also allows for a continuous measure that, in conjunction with possible discordant analysis, could be used in the future to identify possible earlier pathological deposition as well as monitor disease progression and treatment effectiveness.
Collapse
Affiliation(s)
- Marco Bucci
- Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
| | - Irina Savitcheva
- Medical Radiation Physics and Nuclear Medicine, Section for Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden
| | - Gill Farrar
- Pharmaceutical Diagnostics, GE Healthcare, Amersham, UK
| | - Gemma Salvadó
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
| | - Lyduine Collij
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117, Amsterdam, Netherlands
| | - Vincent Doré
- Austin Health, University of Melbourne, Melbourne, Australia.,Health and Biosecurity, CSIRO, Parkville, Australia
| | - Juan Domingo Gispert
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Pompeu Fabra, Barcelona, Spain.,Centro de Investigación Biomédica en Red Bioingenieriá, Biomateriales y Nanomedicina, (CIBER-BBN), Barcelona, Spain
| | - Roger Gunn
- Invicro, London, UK.,Division of Brain Sciences, Department of Medicine, Imperial College, London, UK
| | - Bernard Hanseeuw
- Neurology and Nuclear Medicine Departments, Saint-Luc University Hospital, Av. Hippocrate, 10, 1200, Brussels, Belgium.,Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Oskar Hansson
- Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden
| | - Mahnaz Shekari
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Pompeu Fabra, Barcelona, Spain
| | - Renaud Lhommel
- Neurology and Nuclear Medicine Departments, Saint-Luc University Hospital, Av. Hippocrate, 10, 1200, Brussels, Belgium
| | - José Luis Molinuevo
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.,IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Pompeu Fabra, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain
| | - Christopher Rowe
- Austin Health, University of Melbourne, Melbourne, Australia.,Department of Medicine, The University of Melbourne, Melbourne, Australia
| | | | | | | | - Agneta Nordberg
- Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. .,Department of Aging, Karolinska University Hospital, Stockholm, Sweden.
| |
Collapse
|
22
|
Werion A, Ponlot E, Lhommel R, Komuta M, Coubeau L, Goffin E. An unusual cause of hypercalcaemia in a home haemodialysis patient: Peritoneal tuberculosis. Int J Infect Dis 2020; 104:222-223. [PMID: 33359441 DOI: 10.1016/j.ijid.2020.12.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Revised: 12/17/2020] [Accepted: 12/18/2020] [Indexed: 11/17/2022] Open
Affiliation(s)
- Alexis Werion
- Division of Nephrology, Cliniques Universitaires St Luc, Brussels, Belgium.
| | - Eleonore Ponlot
- Division of Nephrology, Cliniques Universitaires St Luc, Brussels, Belgium
| | - Renaud Lhommel
- Division of Nuclear Medicine, Cliniques Universitaires St Luc, Brussels, Belgium
| | - Mina Komuta
- Division of Pathology, Cliniques Universitaires St Luc, Brussels, Belgium
| | - Laurent Coubeau
- Division of Surgery and Abdominal Transplantation, Cliniques Universitaires St Luc, Brussels, Belgium
| | - Eric Goffin
- Division of Nephrology, Cliniques Universitaires St Luc, Brussels, Belgium
| |
Collapse
|
23
|
Malotaux V, Dricot L, Quenon L, Ivanoiu A, Lhommel R, Hanseeuw B. Alzheimer‐like glucose hypometabolism predicts subsequent dementia in amyloid‐negative mild cognitive impairment. Alzheimers Dement 2020. [DOI: 10.1002/alz.044541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Vincent Malotaux
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
| | - Laurence Dricot
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
| | - Lisa Quenon
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
- Saint Luc University Hospital Université Catholique de Louvain Brussels Belgium
| | - Adrian Ivanoiu
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
- Saint Luc University Hospital Université Catholique de Louvain Brussels Belgium
| | - Renaud Lhommel
- Saint Luc University Hospital Université Catholique de Louvain Brussels Belgium
| | - Bernard Hanseeuw
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
- Saint Luc University Hospital Université Catholique de Louvain Brussels Belgium
- Gordon Center for Medical Imaging Radiology Department Massachusetts General Hospital Boston MA USA
| |
Collapse
|
24
|
Farrar G, Nordberg AK, Sur C, Scott D, Lhommel R, Collij L, Molinuevo JL, Hansson O, Gunn RN, Rowe CC, Dore V, Buckley CJ. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [
18
F]flutemetamol PET images. Alzheimers Dement 2020. [DOI: 10.1002/alz.043157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | | | - Cyrille Sur
- Merck & Co., Inc. / Translational Biomarkers West Point PA USA
| | | | - Renaud Lhommel
- Saint Luc University Hospital Université Catholique de Louvain Brussels Belgium
| | - Lyduine Collij
- Amsterdam UMC VU University Medical Center Amsterdam Netherlands
| | - Jose Luis Molinuevo
- Alzheimer's Disease and Other Cognitive Disorders Unit Hospital Clínic Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Bracelona Spain
| | - Oskar Hansson
- Clinical Memory Research Unit Lund University Malmö Sweden
| | | | | | - Vincent Dore
- The Australian e‐Health Research Centre CSIRO Melbourne Australia
| | | |
Collapse
|
25
|
Woodard JL, Bellaali Y, Dricot L, Lhommel R, Malotaux V, Quenon L, Hanseeuw B, Ivanoiu A. Multivariate prediction of rate of decline in memory functioning over six years using imaging biomarkers. Alzheimers Dement 2020. [DOI: 10.1002/alz.045645] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- John L. Woodard
- Wayne State University Detroit MI USA
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
| | - Youssef Bellaali
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
| | - Laurence Dricot
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
| | - Renaud Lhommel
- Saint Luc University Hospital Université Catholique de Louvain Brussels Belgium
| | - Vincent Malotaux
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
| | - Lisa Quenon
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
| | - Bernard Hanseeuw
- Saint Luc University Hospital Université Catholique de Louvain Brussels Belgium
- Gordon Center for Medical Imaging Radiology Department Massachusetts General Hospital Boston MA USA
| | - Adrian Ivanoiu
- Institute of Neuroscience Université Catholique de Louvain Brussels Belgium
| |
Collapse
|
26
|
Hanseeuw BJ, Malotaux V, Dricot L, Quenon L, Sznajer Y, Cerman J, Woodard JL, Buckley C, Farrar G, Ivanoiu A, Lhommel R. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [ 18F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging 2020; 48:302-310. [PMID: 32601802 PMCID: PMC7835306 DOI: 10.1007/s00259-020-04942-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 06/22/2020] [Indexed: 12/14/2022]
Abstract
PURPOSE To evaluate cerebral amyloid-β(Aβ) pathology in older adults with cognitive complaints, visual assessment of PET images is approved as the routine method for image interpretation. In research studies however, Aβ-PET semi-quantitative measures are associated with greater risk of progression to dementia; but until recently, these measures lacked standardization. Therefore, the Centiloid scale, providing standardized Aβ-PET semi-quantitation, was recently validated. We aimed to determine the predictive values of visual assessments and Centiloids in non-demented patients, using long-term progression to dementia as our standard of truth. METHODS One hundred sixty non-demented participants (age, 54-86) were enrolled in a monocentric [18F] flutemetamol Aβ-PET study. Flutemetamol images were interpreted visually following the manufacturers recommendations. SUVr values were converted to the Centiloid scale using the GAAIN guidelines. Ninety-eight persons were followed until dementia diagnosis or were clinically stable for a median of 6 years (min = 4.0; max = 8.0). Twenty-five patients with short follow-up (median = 2.0 years; min = 0.8; max = 3.9) and 37 patients with no follow-up were excluded. We computed ROC curves predicting subsequent dementia using baseline PET data and calculated negative (NPV) and positive (PPV) predictive values. RESULTS In the 98 participants with long follow-up, Centiloid = 26 provided the highest overall predictive value = 87% (NPV = 85%, PPV = 88%). Visual assessment corresponded to Centiloid = 40, which predicted dementia with an overall predictive value = 86% (NPV = 81%, PPV = 92%). Inclusion of the 25 patients who only had a 2-year follow-up decreased the PPV = 67% (NPV = 88%), reflecting the many positive cases that did not progress to dementia after short follow-ups. CONCLUSION A Centiloid threshold = 26 optimally predicts progression to dementia 6 years after PET. Visual assessment provides similar predictive value, with higher specificity and lower sensitivity. TRIAL REGISTRATION Eudra-CT number: 2011-001756-12.
Collapse
Affiliation(s)
- Bernard J Hanseeuw
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium. .,Neurology Department, Saint-Luc University Hospital, Av. Hippocrate, 10, 1200, Brussels, Belgium. .,Gordon Center for Medical Imaging, Radiology Department, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
| | - Vincent Malotaux
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
| | - Laurence Dricot
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
| | - Lisa Quenon
- Neurology Department, Saint-Luc University Hospital, Av. Hippocrate, 10, 1200, Brussels, Belgium
| | - Yves Sznajer
- Genetics Department, Saint-Luc University Hospital, Brussels, Belgium
| | - Jiri Cerman
- Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic
| | - John L Woodard
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.,Department of Psychology, Wayne State University, Detroit, MI, USA
| | | | | | - Adrian Ivanoiu
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.,Neurology Department, Saint-Luc University Hospital, Av. Hippocrate, 10, 1200, Brussels, Belgium
| | - Renaud Lhommel
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.,Nuclear Medicine Department, Saint-Luc University Hospital, Brussels, Belgium.,Institute of Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium
| |
Collapse
|
27
|
Demols A, Borbath I, Guillaume L, Van Laethem J, Goldman S, Lhommel R. Exploratory analysis based on tumour location and early metabolic tumour response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Malotaux V, Dricot L, Quenon L, Ivanoiu A, Lhommel R, Hanseeuw B. Glucose metabolism in brain regions affected by amyloid predicts cognitive performance in patients with mild cognitive impairment. Front Neurosci 2019. [DOI: 10.3389/conf.fnins.2019.96.00007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
d'Abadie P, Hesse M, Jamar F, Lhommel R, Walrand S. 90Y TOF-PET based EUD reunifies patient survival prediction in resin and glass microspheres radioembolization of HCC tumours. Phys Med Biol 2018; 63:245010. [PMID: 30524029 DOI: 10.1088/1361-6560/aaf205] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Clinical studies reported a twofold ratio between the efficacies per Gy of resin versus glass spheres. Our aim is to investigate whether this difference could result from the different degrees of heterogeneity in sphere distribution between the two medical devices. The 90Y TOF-PET based equivalent uniform doses (EUD) was used for this purpose. 58 consecutive HCC radioembolizations were retrospectively analyzed. Absorbed doses D and Jones-Hoban EUD in lesions were computed. Radioembolization efficacy was assessed using Kaplan-Meier survival curves. In order to match together the glass and resin spheres survival curves using a 40 Gy-threshold, an efficacy factor of 0.73 and 0.36 has to be applied on their absorbed dose, respectively. Using EUD, a nice matching between glass and resin survival curves was obtained with a better separation of the responding and not responding survival curves. The results clearly support the fact that the activity heterogeneity observed in 90Y TOF-PET post radioembolization does not only result from statistical noise, but also reflects the actual heterogeneity of the spheres distribution. Use of EUD reunifies the efficacy of the two medical devices.
Collapse
Affiliation(s)
- P d'Abadie
- Nuclear Medicine, Saint-Luc Hospital, Brussels, Belgium
| | | | | | | | | |
Collapse
|
30
|
Pouleur AC, Anker S, Brito D, Brosteanu O, Hasenclever D, Casadei B, Edelmann F, Filippatos G, Gruson D, Ikonomidis I, Lhommel R, Mahmod M, Neubauer S, Persu A, Gerber BL, Piechnik S, Pieske B, Pieske-Kraigher E, Pinto F, Ponikowski P, Senni M, Trochu JN, Van Overstraeten N, Wachter R, Balligand JL. Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). ESC Heart Fail 2018; 5:830-841. [PMID: 29932311 PMCID: PMC6165933 DOI: 10.1002/ehf2.12306] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 04/22/2018] [Indexed: 12/28/2022] Open
Abstract
Aims Progressive left ventricular (LV) remodelling with cardiac myocyte hypertrophy, myocardial fibrosis, and endothelial dysfunction plays a key role in the onset and progression of heart failure with preserved ejection fraction. The Beta3‐LVH trial will test the hypothesis that the β3 adrenergic receptor agonist mirabegron will improve LV hypertrophy and diastolic function in patients with hypertensive structural heart disease at high risk for developing heart failure with preserved ejection fraction. Methods and results Beta3‐LVH is a randomized, placebo‐controlled, double‐blind, two‐armed, multicentre, European, parallel group study. A total of 296 patients will be randomly assigned to receive either mirabegron 50 mg daily or placebo over 12 months. The main inclusion criterion is the presence of LV hypertrophy, that is, increased LV mass index (LVMi) or increased wall thickening by echocardiography. The co‐primary endpoints are a change in LVMi by cardiac magnetic resonance imaging and a change in LV diastolic function (assessed by the E/e′ ratio). Secondary endpoints include mirabegron's effects on cardiac fibrosis, left atrial volume index, maximal exercise capacity, and laboratory markers. Two substudies will evaluate mirabegron's effect on endothelial function by pulse amplitude tonometry and brown fat activity by positron emission tomography using 17F‐fluorodeoxyglucose. Morbidity and mortality as well as safety aspects will also be assessed. Conclusions Beta3‐LVH is the first large‐scale clinical trial to evaluate the effects of mirabegron on LVMi and diastolic function in patients with LVH. Beta3‐LVH will provide important information about the clinical course of this condition and may have significant impact on treatment strategies and future trials in these patients.
Collapse
Affiliation(s)
- Anne-Catherine Pouleur
- Cardiovascular Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - Stefan Anker
- Innovative Clinical Trials, Department of Cardiology and Pneumology, University Medical Center Göttingen (UMG), Göttingen, Germany.,Division of Cardiology and Metabolism-Heart Failure, Cachexia and Sarcopenia, Department of Cardiology, Berlin Brandenburg Center for Regenerative Therapies, Charité University of Medicine, Berlin, Germany
| | - Dulce Brito
- Department of Cardiology, CHLN, CCUL (Cardiovascular Centre), AIDFM, Hospital de Santa Maria, Universidade de Lisboa, Lisbon, Portugal
| | - Oana Brosteanu
- Clinical Trial Centre Leipzig-ZKS, Faculty of Medicine, Leipzig University, Leipzig, Germany
| | - Dirk Hasenclever
- Institute for Medical Informatics, Statistics & Epidemiology-IMISE, Faculty of Medicine, Leipzig University, Leipzig, Germany
| | - Barbara Casadei
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
| | - Frank Edelmann
- Department of Internal Medicine and Cardiology, Charité-Universitätsmedizin Berlin-Campus Virchow Klinikum, Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany
| | - Gerasimos Filippatos
- National and Kapodistrian University of Athens, School of Medicine and Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, Athens, Greece
| | - Damien Gruson
- Clinical Biology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - Ignatios Ikonomidis
- National and Kapodistrian University of Athens, School of Medicine and Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, Athens, Greece
| | - Renaud Lhommel
- Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - Masliza Mahmod
- Cardiovascular Imaging Core Laboratory, Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Stefan Neubauer
- Cardiovascular Imaging Core Laboratory, Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Alexandre Persu
- Cardiovascular Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - Bernhard L Gerber
- Cardiovascular Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - Stefan Piechnik
- Cardiovascular Imaging Core Laboratory, Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Burkert Pieske
- Department of Internal Medicine and Cardiology, Charité-Universitätsmedizin Berlin-Campus Virchow Klinikum, Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site, Berlin, Germany.,Berlin Institute of Health (BIH), Berlin, Germany.,Department of Internal Medicine and Cardiology, German Heart Institute, Berlin, Germany
| | - Elisabeth Pieske-Kraigher
- Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK
| | - Fausto Pinto
- Division of Cardiology and Metabolism-Heart Failure, Cachexia and Sarcopenia, Department of Cardiology, Berlin Brandenburg Center for Regenerative Therapies, Charité University of Medicine, Berlin, Germany
| | - Piotr Ponikowski
- Department of Heart Diseases, Wrocław Medical University, Wrocław, Poland.,Cardiology Department, Military Hospital, Wrocław, Poland
| | - Michele Senni
- Department Cardiovascular Medicine, Cardiology Division, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - Jean-Noël Trochu
- Institut du thorax, Centre Hospitalier Universitaire de Nantes, Nantes, France.,Medical School, University of Nantes, Nantes, France
| | - Nancy Van Overstraeten
- Cardiovascular Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - Rolf Wachter
- Clinic for Cardiology and Pneumology, University of Göttingen Medical Centre, Göttingen, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Göttingen, Göttingen, Germany
| | - Jean-Luc Balligand
- Department of Medicine, Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Université catholique de Louvain, B1.53.09, 52 avenue Mounier, 1200, Brussels, Belgium
| |
Collapse
|
31
|
Mignion L, Schmitz S, Michoux N, Caignet X, Goebbels RM, Bol A, Neveu MAC, Grégoire V, Duprez T, Lhommel R, Amant F, Hermans E, Jordan BF, Machiels JP. 2'-deoxy-2'-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck. Oncotarget 2018; 9:28572-28585. [PMID: 29983881 PMCID: PMC6033354 DOI: 10.18632/oncotarget.25574] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Accepted: 05/19/2018] [Indexed: 01/29/2023] Open
Abstract
We investigated changes on 2'-deoxy-2'-[18F]fluoro-D-glucose positron emission tomography (18FDG-PET), diffusion-weighted magnetic resonance imaging (DW-MRI), and choline spectroscopy as early markers of cetuximab activity in squamous cell carcinoma of the head and neck (SCCHN). SCCHN patient-derived tumor xenografts models were selected based on their cetuximab sensitivity. Three models were resistant to cetuximab and two were sensitive (one was highly sensitive and the other one was moderately sensitive). Cetuximab was infused on day 0 and 7. Maximal standardized uptake values (SUVmax), apparent diffusion coefficient (ADC), and total choline pool were measured at baseline and at day 8. To investigate the possible clinical relevance of our pre-clinical findings, we also studied the SUVmax and ADC modifications induced by cetuximab in five patients. Cetuximab induced a significant decrease in SUVmax and an increase in ADC at day 8 compared to baseline in the most cetuximab-sensitive model but not in the other models. At day 8, in one resistant model, SUVmax was decreased compared to baseline and was significantly lower than the controls. Choline spectroscopy was not able to predict cetuximab activity. The five patients treated with cetuximab had a 18FDG-PET partial response. One patient had a partial response according to RECISTv1.1. Interestingly, this last had also an increase in ADC value above 25%. Our preclinical data support the use of PDTX to investigate imaging techniques to detect early treatment response. Our pre-clinical and clinical data suggest that DW-MRI and 18FDG-PET should be further investigated to predict cetuximab activity.
Collapse
Affiliation(s)
- Lionel Mignion
- Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Sandra Schmitz
- Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain, Brussels, Belgium
| | - Nicolas Michoux
- Department of Radiology and Medical Imaging, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Xavier Caignet
- Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain, Brussels, Belgium
| | - Rose-Marie Goebbels
- Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain, Brussels, Belgium
| | - Anne Bol
- Center for Molecular Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium
| | - Marie-Aline C Neveu
- Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Vincent Grégoire
- Center for Molecular Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium
| | - Thierry Duprez
- Department of Radiology and Medical Imaging, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Renaud Lhommel
- Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (POLE MIRO), Université Catholique de Louvain, Brussels, Belgium
| | - Fréderic Amant
- Department of Oncology, Gynecologic Oncology, KU Leuven (University of Leuven), Leuven, Belgium
| | - Els Hermans
- Department of Oncology, Gynecologic Oncology, KU Leuven (University of Leuven), Leuven, Belgium
| | - Benedicte F Jordan
- Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute, Université Catholique de Louvain, Brussels, Belgium
| | - Jean-Pascal Machiels
- Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université catholique de Louvain, Brussels, Belgium
| |
Collapse
|
32
|
Machiels JP, Bossi P, Menis J, Lia M, Fortpied C, Liu Y, Lhommel R, Lemort M, Schmitz S, Canevari S, De Cecco L, Guzzo M, Bianchi R, Quattrone P, Crippa F, Duprez T, Lalami Y, Quiriny M, de Saint Aubain N, Clement P, Coropciuc R, Hauben E, Licitra L. Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2018; 29:985-991. [DOI: 10.1093/annonc/mdy013] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
33
|
Walrand S, Hesse M, Jamar F, Lhommel R. The origin and reduction of spurious extrahepatic counts observed in 90Y non-TOF PET imaging post radioembolization. Phys Med Biol 2018. [PMID: 29513273 DOI: 10.1088/1361-6560/aab4e9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Our literature survey revealed a physical effect unknown to the nuclear medicine community, i.e. internal bremsstrahlung emission, and also the existence of long energy resolution tails in crystal scintillation. None of these effects has ever been modelled in PET Monte Carlo (MC) simulations. This study investigates whether these two effects could be at the origin of two unexplained observations in 90Y imaging by PET: the increasing tails in the radial profile of true coincidences, and the presence of spurious extrahepatic counts post radioembolization in non-TOF PET and their absence in TOF PET. These spurious extrahepatic counts hamper the microsphere delivery check in liver radioembolization. An acquisition of a 32P vial was performed on a GSO PET system. This is the ideal setup to study the impact of bremsstrahlung x-rays on the true coincidence rate when no positron emission and no crystal radioactivity are present. A MC simulation of the acquisition was performed using Gate-Geant4. MC simulations of non-TOF PET and TOF-PET imaging of a synthetic 90Y human liver radioembolization phantom were also performed. Internal bremsstrahlung and long energy resolution tails inclusion in MC simulations quantitatively predict the increasing tails in the radial profile. In addition, internal bremsstrahlung explains the discrepancy previously observed in bremsstrahlung SPECT between the measure of the 90Y bremsstrahlung spectrum and its simulation with Gate-Geant4. However the spurious extrahepatic counts in non-TOF PET mainly result from the failure of conventional random correction methods in such low count rate studies and poor robustness versus emission-transmission inconsistency. A novel proposed random correction method succeeds in cleaning the spurious extrahepatic counts in non-TOF PET. Two physical effects not considered up to now in nuclear medicine were identified to be at the origin of the unusual 90Y true coincidences radial profile. TOF reconstruction removing of the spurious extrahepatic counts was theoretically explained by a better robustness against emission-transmission inconsistency. A novel random correction method was proposed to overcome the issue in non-TOF PET. Further studies are needed to assess the novel random correction method robustness.
Collapse
|
34
|
Hanseeuw B, Dricot L, Lhommel R, Quenon L, Ivanoiu A. Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved. J Alzheimers Dis 2018; 53:651-60. [PMID: 27232217 DOI: 10.3233/jad-160204] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Patients with mild cognitive impairment (MCI) are at risk for Alzheimer's dementia but the presence of amyloid (Aβ) strongly increases this risk. In clinical settings, when Aβ status is not available, different neurodegenerative markers are used to characterize MCI. The accuracy of these markers to discriminate between Aβ-and Aβ+ MCI is not yet determined. OBJECTIVE To compare different markers of neurodegeneration in Aβ-and Aβ+ MCI, with an Aβ-elderly control (EC) group. METHODS Patients with MCI (n = 39) and EC (n = 28) underwent MRI, 18F-FDG PET, and Aβ PET (18F-flutemetamol). We compared FDG and MRI biomarker values in cortical and hippocampal regions of interest, and using voxel-wise surface maps. We computed ROC curves discriminating between the three groups for each biomarker. RESULTS All biomarker values were reduced in Aβ+ MCI compared to EC (p < 0.001). Aβ-MCI had low cortical metabolism (p = 0.002), but hippocampal volume, cortical thickness, and hippocampal metabolism were not significantly different between Aβ-MCI and EC (p > 0.40). Cortical metabolism best discriminated between MCI and EC (AUC = 0.92/0.86, Aβ+/Aβ-) while hippocampal volume best discriminated between Aβ-MCI and Aβ+ MCI (AUC = 0.79). CONCLUSIONS Cortical hypometabolism was observed in both Aβ-MCI and Aβ+ MCI whereas hippocampal atrophy was mostly found in Aβ+ MCI. For MCI patients without available Aβ information, hippocampal atrophy is thus more informative about Aβ status than cortical hypometabolism.
Collapse
Affiliation(s)
- Bernard Hanseeuw
- Neurology Department, Saint-Luc University Hospital, Brussels, Belgium.,Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium.,Neurology Department, Massachusetts General Hospital and the Martinos Center for Biomedical Imaging, Boston, MA, USA
| | - Laurence Dricot
- Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
| | - Renaud Lhommel
- Nuclear Medicine Department, Saint-Luc University Hospital, Brussels, Belgium
| | - Lisa Quenon
- Neurology Department, Saint-Luc University Hospital, Brussels, Belgium.,Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
| | - Adrian Ivanoiu
- Neurology Department, Saint-Luc University Hospital, Brussels, Belgium.,Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium
| |
Collapse
|
35
|
Mertes H, Defourny L, Tré-Hardy M, Lhommel R, El Khoury G, Rodriguez-Villalobos H, Belkhir L. First Robinsoniella peoriensis aortic cross homograft mycotic pseudoaneurysm: A case report and review of the literature. Anaerobe 2016; 44:23-26. [PMID: 28043924 DOI: 10.1016/j.anaerobe.2016.12.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 12/28/2016] [Accepted: 12/29/2016] [Indexed: 11/27/2022]
Abstract
Mycotic aortic aneurysm is a rare and challenging complication of aortic homografts caused by an infection and is associated with high morbidity and mortality. We report the first case of an aortic cross homograft mycotic pseudoaneurysm caused by Robinsoniella peoriensis in a 70-year-old man. Our patient underwent surgery for a recurrence of aortic cross mycotic pseudoaneurysm at the level of the aortic homograft he had had 7 years before. A clot-removal of the pseudoaneurysm was surgically carried out and the homograft was completely removed. Anaerobic culture from tissue samples yielded pure growth of a spore-forming Gram-positive rod, identified later as Robinsoniella peoriensis by 16S rRNA gene sequencing. The patient was then discharged with oral clindamycin according to the in vitro susceptibility testing. Identification of R. peoriensis might be challenging in clinical laboratories with no access to molecular methods.
Collapse
Affiliation(s)
- H Mertes
- Cliniques Universitaires St. Luc, Internal Medicine and Infectious Diseases Department, Avenue Hippocrate 10, 1200 Brussels, Belgium.
| | - L Defourny
- Cliniques Universitaires St. Luc, Clinical Microbiology Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| | - M Tré-Hardy
- Cliniques Universitaires St. Luc, Clinical Microbiology Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| | - R Lhommel
- Cliniques Universitaires St. Luc, Nuclear Medicine Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| | - G El Khoury
- Cliniques Universitaires St. Luc, Cardiovascular Surgery Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| | - H Rodriguez-Villalobos
- Cliniques Universitaires St. Luc, Clinical Microbiology Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| | - L Belkhir
- Cliniques Universitaires St. Luc, Internal Medicine and Infectious Diseases Department, Avenue Hippocrate 10, 1200 Brussels, Belgium
| |
Collapse
|
36
|
Pierrot N, Lhommel R, Quenon L, Hanseeuw B, Dricot L, Sindic C, Maloteaux JM, Octavea JN, Ivanoiu A. Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease. J Alzheimers Dis 2016; 49:271-6. [PMID: 26444777 DOI: 10.3233/jad-150405] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We present the effects of Targretin® (bexarotene) on cognition and biomarkers in a patient with mild Alzheimer's disease (AD). Targretin® is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux. After 6 months of treatment with Targretin® 300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20% . No significant side effects were noticed. This observation in a single patient indicates that Targretin® may improve memory performance and biological markers at an early stage of AD.
Collapse
Affiliation(s)
- Nathalie Pierrot
- Université catholique de Louvain, Brussels, Belgium.,Institute of Neuroscience, Brussels, Belgium
| | - Renaud Lhommel
- Université catholique de Louvain, Brussels, Belgium.,Institute of Neuroscience, Brussels, Belgium.,Cliniques universitaires Saint Luc, Nuclear Medicine department, Brussels, Belgium
| | - Lisa Quenon
- Université catholique de Louvain, Brussels, Belgium.,Institute of Neuroscience, Brussels, Belgium
| | - Bernard Hanseeuw
- Université catholique de Louvain, Brussels, Belgium.,Cliniques universitaires Saint Luc, Neurology department, Brussels, Belgium
| | - Laurence Dricot
- Université catholique de Louvain, Brussels, Belgium.,Institute of Neuroscience, Brussels, Belgium
| | - Christian Sindic
- Université catholique de Louvain, Brussels, Belgium.,Institute of Neuroscience, Brussels, Belgium
| | - Jean-Marie Maloteaux
- Université catholique de Louvain, Brussels, Belgium.,Institute of Neuroscience, Brussels, Belgium.,Cliniques universitaires Saint Luc, Neurology department, Brussels, Belgium
| | - Jean-Noël Octavea
- Université catholique de Louvain, Brussels, Belgium.,Institute of Neuroscience, Brussels, Belgium
| | - Adrian Ivanoiu
- Université catholique de Louvain, Brussels, Belgium.,Institute of Neuroscience, Brussels, Belgium.,Cliniques universitaires Saint Luc, Neurology department, Brussels, Belgium
| |
Collapse
|
37
|
Machiels JPH, Menis J, Lia M, Fortpied C, Lhommel R, Lemort M, Guzzo M, Bianchi R, Crippa F, Quattrone P, Bossi P, Schmitz S, Duprez T, Lalami Y, Quiriny M, de Saint Aubain N, Clement PM, Coropciuc R, Hauben E, Licitra LF. Activity of afatinib administered in a window pre-operative study in squamous cell carcinoma of the head and neck (SCCHN) : EORTC-90111. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.6049] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Jessica Menis
- European Organization for Research and Treatment of Cancer, Brussels, Belgium
| | | | | | - Renaud Lhommel
- Department of Nuclear Medicine, St-Luc Hospital, Catholic University of Louvain, Brussels, Belgium
| | - Marc Lemort
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Marco Guzzo
- Fondazione IRCCS Istituto Nazionale Tumori, Milano, Milan, Italy
| | - Roberto Bianchi
- Fondazione IRCCS Istituto Nazionale Tumori, Milano, Milano, Italy
| | - Flavio Crippa
- Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
| | - Pasquale Quattrone
- 4 Pathology Dept.,Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Paolo Bossi
- Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - Sandra Schmitz
- Department of Head and Neck Surgery, St-Luc Hospital, Catholic University of Louvain, Brussels, Belgium
| | - Thierry Duprez
- Department of Radiology, St-Luc Hospital, Catholic University of Louvain, Brussels, Belgium
| | | | | | | | | | - Ruxandra Coropciuc
- Department of Oral and Maxillofacial Surgery, UZ Leuven, Leuven, Belgium
| | | | - Lisa F. Licitra
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
38
|
Woff E, Hendlisz A, Garcia C, Deleporte A, Delaunoit T, Maréchal R, Holbrechts S, Van den Eynde M, Demolin G, Vierasu I, Lhommel R, Gauthier N, Guiot T, Ameye L, Flamen P. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. Eur J Nucl Med Mol Imaging 2016; 43:1792-801. [PMID: 27072811 PMCID: PMC4969337 DOI: 10.1007/s00259-016-3365-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Accepted: 03/08/2016] [Indexed: 12/19/2022]
Abstract
Introduction The introduction of targeted drugs has had a significant impact on the approach to assessing tumour response. These drugs often induce a rapid cytostatic effect associated with a less pronounced and slower tumoural volume reduction, thereby impairing the correlation between the absence of tumour shrinkage and the patient’s unlikelihood of benefit. The aim of the study was to assess the predictive value of early metabolic response (mR) evaluation after one cycle, and its interlesional heterogeneity to a later metabolic and morphological response assessment performed after three cycles in metastatic colorectal cancer (mCRC) patients treated with combined sorafenib and capecitabine. Methods This substudy was performed within the framework of a wider prospective multicenter study on the predictive value of early FDG PET-CT response assessment (SoMore study). A lesion-based response analysis was performed, including all measurable lesions identified on the baseline PET. On a per-patient basis, a descriptive 4-class response categorization was applied based upon the presence and proportion of non-responding lesions. For dichotomic response comparison, all patients with at least one resistant lesion were classified as non-responding. Results On baseline FDG PET-CT, 124 measurable “target” lesions were identified in 38 patients. Early mR assessments showed 18 patients (47 %) without treatment resistant lesions and 12 patients (32 %) with interlesional response heterogeneity. The NPV and PPV of early mR were 85 % (35/41) and 84 % (70/83), respectively, on a per-lesion basis and 95 % (19/20) and 72 % (13/18), respectively, on a dichotomized per-patient basis. Conclusions Early mR assessment performed after one cycle of sorafenib-capecitabine in mCRC is highly predictive of non-response at a standard response assessment time. The high NPV (95 %) of early mR could be useful as the basis for early treatment discontinuation or adaptation to spare patients from exposure to non-effective drugs.
Collapse
Affiliation(s)
- Erwin Woff
- Nuclear Medicine Department, Institut Jules Bordet, Université libre de Bruxelles, 1 rue Héger-Bordet, 1000, Brussels, Belgium.
| | - Alain Hendlisz
- Medical Oncology Department, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium
| | - Camilo Garcia
- Nuclear Medicine Department, Institut Jules Bordet, Université libre de Bruxelles, 1 rue Héger-Bordet, 1000, Brussels, Belgium
| | - Amelie Deleporte
- Medical Oncology Department, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium
| | | | - Raphaël Maréchal
- Gastroenterology Medico-Surgical Department, Erasme University Hospital, Université libre de Bruxelles, Brussels, Belgium
| | | | - Marc Van den Eynde
- Oncology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | | | - Irina Vierasu
- Nuclear Medicine Department, Erasme University Hospital, Université libre de Bruxelles, Brussels, Belgium
| | - Renaud Lhommel
- Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - Namur Gauthier
- Nuclear Medicine Department, CHC Saint-Joseph, Liège, Belgium
| | - Thomas Guiot
- Nuclear Medicine Department, Institut Jules Bordet, Université libre de Bruxelles, 1 rue Héger-Bordet, 1000, Brussels, Belgium
| | - Lieveke Ameye
- Data center Department, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium
| | - Patrick Flamen
- Nuclear Medicine Department, Institut Jules Bordet, Université libre de Bruxelles, 1 rue Héger-Bordet, 1000, Brussels, Belgium
| |
Collapse
|
39
|
Affiliation(s)
- N Guischer
- 1 Rheumatology Department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium
| | - F A Houssiau
- 1 Rheumatology Department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium
| | - R Lhommel
- 2 Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium
| | - E Coche
- 3 Radiology Department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium
| | - V Roelants
- 2 Nuclear Medicine Department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium
| |
Collapse
|
40
|
Ivanoiu A, Dricot L, Gilis N, Grandin C, Lhommel R, Quenon L, Hanseeuw B. Classification of non-demented patients attending a memory clinic using the new diagnostic criteria for Alzheimer's disease with disease-related biomarkers. J Alzheimers Dis 2015; 43:835-47. [PMID: 25114071 DOI: 10.3233/jad-140651] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND New diagnostic criteria for predemential Alzheimer's disease (AD) advocate the use of biomarkers. However, the benefit of using biomarkers has not been clearly demonstrated in clinical practice. OBJECTIVE To investigate whether a combination of biomarkers may be helpful in classifying a population of non-demented patients attending a Memory Clinic. METHODS Sixty non-demented patients were compared with 31 healthy elderly subjects. All subjects underwent a neuropsychological examination, brain 3T magnetic resonance imaging, [F18]-fluorodeoxyglucose and [F18]-flutemetamol positron emission tomography. According to their performance on memory, language, executive, and visuo-spatial domains, the patients were classified as mild cognitive impairment (amnestic, non-amnestic, single, or multiple domain) or subjective cognitive impairment. Patients were then classified according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria, using the normalized mean hippocampal volume (Freesurfer), [F18]-FDG PALZAD, and [F18]-flutemetamol standard uptake value ratio (SUVr) (cut-off at the 10th percentile of controls). The standard of truth was the clinical status at study entry (patient versus control). RESULTS The sensitivity/specificity of the clinical classification was 65/84%. The NIA-AA criteria were applicable in 85% of patients and 87% of controls. For biomarkers the best sensitivity (72%) at a fixed specificity of 84% was achieved by a combination of the three biomarkers. The clinical diagnosis was reconsidered in more than one third of the patients (42%) as a result of including the biomarker results. CONCLUSIONS Application of the new NIA-AA AD diagnostic criteria based on biomarkers in an unselected sample of non-demented patients attending a Memory Clinic was useful in allowing for a better classification of the subjects.
Collapse
Affiliation(s)
- Adrian Ivanoiu
- Neurology Department, Saint Luc University Hospital, Université catholique de Louvain, Brussels, Belgium Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium
| | - Laurence Dricot
- Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium
| | - Nathalie Gilis
- Neurology Department, Saint Luc University Hospital, Université catholique de Louvain, Brussels, Belgium
| | - Cécile Grandin
- Radiology Department, Saint Luc University Hospital, Université catholique de Louvain, Brussels, Belgium Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium
| | - Renaud Lhommel
- Nuclear Medicine Department, Saint Luc University Hospital, Université catholique de Louvain, Brussels, Belgium
| | - Lisa Quenon
- Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium
| | - Bernard Hanseeuw
- Neurology Department, Saint Luc University Hospital, Université catholique de Louvain, Brussels, Belgium Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium
| |
Collapse
|
41
|
Huart C, Rombaux P, Gérard T, Hanseeuw B, Lhommel R, Quenon L, Ivanoiu A, Mouraux A. Unirhinal Olfactory Testing for the Diagnostic Workup of Mild Cognitive Impairment. J Alzheimers Dis 2015; 47:253-70. [DOI: 10.3233/jad-141494] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Caroline Huart
- Institute of Neuroscience (IoNS), Université catholique de Louvain, Brussels, Belgium
- Department of Otorhinolaryngology, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - Philippe Rombaux
- Institute of Neuroscience (IoNS), Université catholique de Louvain, Brussels, Belgium
- Department of Otorhinolaryngology, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - Thomas Gérard
- Department of Nuclear Medicine, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - Bernard Hanseeuw
- Institute of Neuroscience (IoNS), Université catholique de Louvain, Brussels, Belgium
- Department of Neurology, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - Renaud Lhommel
- Institute of Neuroscience (IoNS), Université catholique de Louvain, Brussels, Belgium
- Department of Nuclear Medicine, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - Lisa Quenon
- Institute of Neuroscience (IoNS), Université catholique de Louvain, Brussels, Belgium
| | - Adrian Ivanoiu
- Institute of Neuroscience (IoNS), Université catholique de Louvain, Brussels, Belgium
- Department of Neurology, Cliniques universitaires Saint-Luc, Brussels, Belgium
| | - André Mouraux
- Institute of Neuroscience (IoNS), Université catholique de Louvain, Brussels, Belgium
| |
Collapse
|
42
|
Jamar F, Lhommel R. Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: Emerging Worldwide? J Nucl Med 2015; 56:655-6. [DOI: 10.2967/jnumed.114.151183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Accepted: 02/06/2015] [Indexed: 11/16/2022] Open
|
43
|
Affiliation(s)
- Stephan Walrand
- Université Catholique de Louvain Av. Hippocrate 10 1200 Bruxelles, Belgium. E-mail:
| | - Michel Hesse
- Université Catholique de Louvain Av. Hippocrate 10 1200 Bruxelles, Belgium. E-mail:
| | - Renaud Lhommel
- Université Catholique de Louvain Av. Hippocrate 10 1200 Bruxelles, Belgium. E-mail:
| | - François Jamar
- Université Catholique de Louvain Av. Hippocrate 10 1200 Bruxelles, Belgium. E-mail:
| |
Collapse
|
44
|
Hanseeuw B, Dricot L, Grandin C, Lhommel R, Quenon L, Ivanoiu A. O2‐03‐02: REGIONAL BRAIN METABOLISM AND CORTICAL THICKNESS IN F18‐FLUTEMETAMOL AMYLOID‐POSITIVE VERSUS ‐NEGATIVE MILD COGNITIVE IMPAIRMENT PATIENTS. Alzheimers Dement 2014. [DOI: 10.1016/j.jalz.2014.04.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
| | | | | | | | - Lisa Quenon
- Université Catholique de LouvainBrusselsBelgium
| | - Adrian Ivanoiu
- Université Catholique de Louvain, Saint Luc HospitalBrusselsBelgium
| |
Collapse
|
45
|
Walrand S, Hesse M, Wojcik R, Lhommel R, Jamar F. Optimal design of anger camera for bremsstrahlung imaging: monte carlo evaluation. Front Oncol 2014; 4:149. [PMID: 24982849 PMCID: PMC4056384 DOI: 10.3389/fonc.2014.00149] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Accepted: 05/29/2014] [Indexed: 11/29/2022] Open
Abstract
A conventional Anger camera is not adapted to bremsstrahlung imaging and, as a result, even using a reduced energy acquisition window, geometric x-rays represent <15% of the recorded events. This increases noise, limits the contrast, and reduces the quantification accuracy. Monte Carlo (MC) simulations of energy spectra showed that a camera based on a 30-mm-thick BGO crystal and equipped with a high energy pinhole collimator is well-adapted to bremsstrahlung imaging. The total scatter contamination is reduced by a factor 10 versus a conventional NaI camera equipped with a high energy parallel hole collimator enabling acquisition using an extended energy window ranging from 50 to 350 keV. By using the recorded event energy in the reconstruction method, shorter acquisition time and reduced orbit range will be usable allowing the design of a simplified mobile gantry. This is more convenient for use in a busy catheterization room. After injecting a safe activity, a fast single photon emission computed tomography could be performed without moving the catheter tip in order to assess the liver dosimetry and estimate the additional safe activity that could still be injected. Further long running time MC simulations of realistic acquisitions will allow assessing the quantification capability of such system. Simultaneously, a dedicated bremsstrahlung prototype camera reusing PMT–BGO blocks coming from a retired PET system is currently under design for further evaluation.
Collapse
Affiliation(s)
- Stephan Walrand
- Department of Nuclear Medicine, Molecular Imaging, Radiotherapy and Oncology Unit (MIRO), IECR, Université Catholique de Louvain , Brussels , Belgium
| | - Michel Hesse
- Department of Nuclear Medicine, Molecular Imaging, Radiotherapy and Oncology Unit (MIRO), IECR, Université Catholique de Louvain , Brussels , Belgium
| | | | - Renaud Lhommel
- Department of Nuclear Medicine, Molecular Imaging, Radiotherapy and Oncology Unit (MIRO), IECR, Université Catholique de Louvain , Brussels , Belgium
| | - François Jamar
- Department of Nuclear Medicine, Molecular Imaging, Radiotherapy and Oncology Unit (MIRO), IECR, Université Catholique de Louvain , Brussels , Belgium
| |
Collapse
|
46
|
Walrand S, Hesse M, Jamar F, Lhommel R. A hepatic dose-toxicity model opening the way toward individualized radioembolization planning. J Nucl Med 2014; 55:1317-22. [PMID: 24904111 DOI: 10.2967/jnumed.113.135301] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2013] [Accepted: 04/09/2014] [Indexed: 12/19/2022] Open
Abstract
UNLABELLED The 50% normal-tissue complication probability (NTCP) after lobar irradiation of the liver results in highly variable biologic effective doses depending on the modality used: a biologic effective dose for 50% (BED50) of 115, 93, and 250 Gy for external-beam radiotherapy, resin microsphere radioembolization, and glass microsphere radioembolization, respectively. This misunderstood property has made it difficult to predict the maximal tolerable dose as a function of microsphere activity and targeted liver volume. The evolution toward more selective catheterization techniques, resulting in more variable targeted volumes, makes it urgent to solve this issue. METHODS We computed by Monte Carlo simulations the microsphere distribution in the portal triads based on microsphere transport dynamics through a synthetically grown hepatic arterial tree. Afterward, the microscale dose distribution was computed using a dose deposition kernel. We showed that the equivalent uniform dose cannot handle microscale dosimetry and fails to solve the discordance between the BED50 values. Consequently, we developed a new radiobiologic model to compute the liver NTCP from the microscale dose distribution. RESULTS The new model explains all the observed BED50 values and provides a way to compute the hepatic dose-toxicity relationship as a function of microsphere activity and targeted liver volume. The NTCP obtained is in agreement with the data reported from clinical radioembolization studies. CONCLUSION The results should encourage interventional radiologists to fine-tune the delivered dose to the liver as a function of the targeted volume. The present model could be used as the backbone of the treatment planning, allowing optimization of the absorbed dose to the tumors.
Collapse
Affiliation(s)
- Stephan Walrand
- Nuclear Medicine, Molecular Imaging, Radiotherapy, and Oncology Unit (MIRO), IECR, Université Catholique de Louvain, Brussels, Belgium
| | - Michel Hesse
- Nuclear Medicine, Molecular Imaging, Radiotherapy, and Oncology Unit (MIRO), IECR, Université Catholique de Louvain, Brussels, Belgium
| | - Francois Jamar
- Nuclear Medicine, Molecular Imaging, Radiotherapy, and Oncology Unit (MIRO), IECR, Université Catholique de Louvain, Brussels, Belgium
| | - Renaud Lhommel
- Nuclear Medicine, Molecular Imaging, Radiotherapy, and Oncology Unit (MIRO), IECR, Université Catholique de Louvain, Brussels, Belgium
| |
Collapse
|
47
|
Deleporte A, Hendlisz A, Garcia C, Delaunoit T, Maréchal R, Peeters M, Holbrechts S, Van Den Eynde M, Houbiers G, Filleul B, Van Laethem JL, Rolfo CD, Diaz M, Lhommel R, Demolin G, Moreau M, Ameye L, Paesmans M, Piccart-Gebhart MJ, Flamen P. SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.3_suppl.524] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
524 Background: The SOR-CAP combination has shown clinical activity in several phase I-II trials involving metastatic breast cancer and mCRC patients (pts). SoMore aims to substantiate the combination’s effects in mCRC refractory to all medications and the predictive value of early metabolic response (MR) on survival. Methods: SoMore (EUDRACT 2010-023695-91) has 2 coprimary objectives: 1) to demonstrate an overall survival (OS) rate at 6 months (mths) > 30%, and 2) to compare OS between pts with and without MR. CAP was given at 1700 mg/m²/day (D), 2 weeks out of 3. SOR was administered at 600mg/D for the first cycle, then at 800mg/D until progression or unacceptable toxicity. FDGPET-CT was performed at baseline and before the 2nd cycle. MR analysis was centralized and blinded for the investigators. Results: From February to October 2011, 92 eligible pts were prospectively recruited in 6 Belgian centers: M/F: 54%/46%; ECOG PS 0/1: 55%/45%; median age: 61. A median of 5 treatment cycles were given (0-28+). Grade 3-4 toxic reactions were reported in 61.2%, mainly fatigue (18%), hand-foot skin reaction (14%) and diarrhea (11%), but no toxic death. 6.9% of the pts stopped therapy due to toxicity. 6 mths OS was 71% (95% CI: 61%-79%), significantly >30% (p<0.001). 47% of the 79 pts evaluable for metabolic assessment showed homogeneous MR (HMR) of all metastatic lesions, 32% mixed MR and 21% homogeneous non-MR. Median overall OS and PFS of the intent-to-treat population and of pts with and without HMR are shown in the table below. Hazard ratio for HMR was 0.34 (95% CI, 0.21 to 0.56) p-value <0.001 for PFS and 0.59 (95% CI, 0.37 to 0.96) p-value 0.03 for OS. Conclusions: These data suggest robust efficacy for the SOR-CAP combination in heavily pretreated mCRC, associated with high but manageable toxicity. Early MR assessment, by detecting unresponsive lesions within the whole body tumoral load, is able to capture the pts’ likelihood of benefit, opening the path to personalized medicine. Clinical trial information: NCT01290926. [Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Marie Diaz
- Centre Hospitalier Universitaire Ambroise Paré, Mons, Belgium
| | - Renaud Lhommel
- Department of Nuclear Medicine, St-Luc Hospital, Catholic University of Louvain, Brussels, Belgium
| | | | | | - Lieveke Ameye
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Marianne Paesmans
- Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | | | | |
Collapse
|
48
|
Walrand S, Hesse M, Chiesa C, Lhommel R, Jamar F. The Low Hepatic Toxicity per Gray of 90Y Glass Microspheres Is Linked to Their Transport in the Arterial Tree Favoring a Nonuniform Trapping as Observed in Posttherapy PET Imaging. J Nucl Med 2013; 55:135-40. [DOI: 10.2967/jnumed.113.126839] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
49
|
Michel C, Dricot L, Lhommel R, Grandin C, Ivanoiu A, Pillon A, Samson D. Extensive left temporal pole damage does not impact on theory of mind abilities. J Cogn Neurosci 2013; 25:2025-46. [PMID: 24047381 DOI: 10.1162/jocn_a_00488] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
The temporal poles (TPs) are among the brain regions that are often considered as the brain network sustaining our ability to understand other people's mental states or "Theory of Mind" (ToM). However, so far the functional role of the left and right TPs in ToM is still debated, and it is even not clear yet whether these regions are necessary for ToM. In this study, we tested whether the left TP is necessary for ToM by assessing the mentalizing abilities of a patient (C.M.) diagnosed with semantic dementia. Converging evidence from detailed MRI and (18)F-fluoro-2-deoxy-d-glucose PET examinations showed a massive atrophy of the left TP with the right TP being relatively unaffected. Furthermore, C.M.'s atrophy encompassed most regions of the left TP usually activated in neuroimaging studies investigating ToM. Given C.M.'s language impairments, we used a battery of entirely nonverbal ToM tasks. Across five tasks encompassing 100 trials, which probed the patient's ability to attribute various mental states (intentions, knowledge, and beliefs), C.M. showed a totally spared performance. This finding suggests that, despite its consistently observed activation in neuroimaging studies involving ToM tasks, the left TP is not necessary for ToM reasoning, at least in nonverbal conditions and as long as its right counterpart is preserved. Implications for understanding the social abilities of patients with semantic dementia are discussed.
Collapse
Affiliation(s)
- Caroline Michel
- Psychological Sciences Research Institute, Université catholique de Louvain, Louvain-la-Neuve, Belgium
| | | | | | | | | | | | | |
Collapse
|
50
|
Nols N, Mounier N, Bouazza S, Lhommel R, Costantini S, Vander Borght T, Vekemans MC, Sonet A, Bosly A, Michaux L, André M, Van Den Neste E. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma 2013; 55:773-80. [PMID: 23927393 DOI: 10.3109/10428194.2013.831848] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The prognostic value of interim (18)fluorodeoxyglucose positron emission tomography (i-PET) was investigated in 73 patients (median age 60 years) with diffuse large B-cell lymphoma (DLBCL). i-PET was analyzed using the Deauville score (DS) and change in maximum standardized uptake value (ΔSUV(max)). Patients with a DS of 1-3 demonstrated a significantly (p < 0.0001) better outcome (median follow-up 2.4 years) than patients with a score of 4 or 5 in terms of event-free survival (EFS) (79% vs. 36%), progression-free survival (PFS) (84% vs. 47%) and overall survival (OS) (91% vs. 51%). EFS (73% vs. 42%), PFS (78% vs. 50%) and OS (88% vs. 56%) were also significantly (p = 0.023) different between patients with ΔSUV(max) > 66% or ≤ 66%. Patients (n = 33) combining a favorable age-adjusted International Prognostic Index (IPI) (0 or 1) and a negative i-PET either by DS or ΔSUV(max) criteria showed a particularly good outcome (EFS: 85%, PFS: 88%, OS: 94%). Overall, i-PET was highly and independently predictive of any outcome, and its negative predictive value was improved by combination with IPI.
Collapse
Affiliation(s)
- Nathalie Nols
- Services de Médecine Nucléaire et d'Hématologie , CHU Mont-Godinne, Yvoir , Belgium
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|